



(86) Date de dépôt PCT/PCT Filing Date: 2016/10/26
(87) Date publication PCT/PCT Publication Date: 2017/05/04
(45) Date de délivrance/Issue Date: 2024/05/14
(85) Entrée phase nationale/National Entry: 2018/04/16
(86) N° demande PCT/PCT Application No.: US 2016/058875
(87) N° publication PCT/PCT Publication No.: 2017/075061
(30) Priorité/Priority: 2015/10/30 (US62/249,097)

(51) Cl.Int./Int.Cl. *C12Q 1/68* (2018.01)
(72) Inventeurs/Inventors:
ALLAWI, HATIM, US;
LIDGARD, GRAHAM P., US;
AIZENSTEIN, BRIAN, US;
SANDER, TAMARA J., US;
GIAKOUMOPOULOS, MARIA, US;
KAISER, MICHAEL W., US;
GRAY, MELISSA M., US;
VACCARO, ABRAM MICHAEL, US
(73) Propriétaire/Owner:
EXACT SCIENCES CORPORATION, US
(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : DETECTION PAR AMPLIFICATION MULTIPLEXÉE ET ISOLEMENT ET DETECTION D'ADN ISSU DE PLASMA
(54) Title: MULTIPLEX AMPLIFICATION DETECTION ASSAY AND ISOLATION AND DETECTION OF DNA FROM PLASMA

(57) Abrégé/Abstract:

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/075061 A1

(43) International Publication Date
4 May 2017 (04.05.2017)

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2016/058875

(22) International Filing Date:
26 October 2016 (26.10.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/249,097 30 October 2015 (30.10.2015) US

(71) Applicant: **EXACT SCIENCES CORPORATION**
[US/US]; 441 Charmany Drive, Madison, Wisconsin
53719 (US).

(72) Inventors: **ALLAWI, Hatim**; 441 Charmany Drive,
Madison, Wisconsin 53719 (US). **LIDGARD, Graham P.**;
441 Charmany Drive, Madison, Wisconsin 53719 (US).
AIZENSTEIN, Brian; 441 Charmany Drive, Madison,
Wisconsin 53719 (US). **SANDER, Tamara J.**; 441 Char-
many Drive, Madison, Wisconsin 53719 (US). **GIAKOU-**
MOPOULOS, Maria; 441 Charmany Drive, Madison,
Wisconsin 53719 (US). **KAISER, Michael W.**; 441 Char-
many Drive, Madison, Wisconsin 53719 (US). **GRAY,**
Melissa M.; 441 Charmany Drive, Madison, Wisconsin
53719 (US). **VACCARO, Abram Michael**; 441 Char-
many Drive, Madison, Wisconsin 53719 (US).

(74) Agent: **BROW, Mary Ann D.**; 2275 Deming Way, Ste
310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTIPLEX AMPLIFICATION DETECTION ASSAY AND ISOLATION AND DETECTION OF DNA FROM PLASMA

(57) Abstract: Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.



WO 2017/075061 A1

MULTIPLEX AMPLIFICATION DETECTION ASSAY AND ISOLATION AND DETECTION OF DNA FROM PLASMA

CROSS-REFERENCE TO RELATED APPLICATIONS.

The present application claims priority to U.S. Provisional Application Serial No. 62/249,097, filed October 30, 2015.

FIELD OF THE INVENTION

Provided herein is technology relating to the amplification-based detection of nucleic acids and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, *e.g.*, plasma samples.

BACKGROUND

Methods for the quantification of nucleic acids are important in many areas of molecular biology and in particular for molecular diagnostics. At the DNA level, such methods are used, for example, to determine the presence or absence of variant alleles, the copy numbers of gene sequences amplified in a genome, and the amount, presence, or absence of methylation across genes or at specific loci within genes. Further, methods for the quantification of nucleic acids are used to determine mRNA quantities as a measure of gene expression.

Among the number of different analytical methods that detect and quantify nucleic acids or nucleic acid sequences, variants of the polymerase chain reaction (PCR) have become the most powerful and widespread technology, the principles of which are disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,965,188.

Detection of nucleic acids that are present at low levels in samples (*e.g.*, such as DNA from a disease locus, *e.g.*, a tumor, that is collected from a sample that is remote from the disease locus, *e.g.*, DNA that finds its way into stool, sputum, urine, plasma, *etc.*, “remote DNA samples”) can be difficult, in part because many DNAs found in such samples are not only present in low amounts, they are also generally fragmented. See, *e.g.*, WO 2006/113770 to Ballhause, and US Patent Publication US 201110009277 A1, to Davos. For example, cell-free DNA (cfDNA) found in plasma can be highly fragmented, and much of the DNA that might be of interest, *e.g.*, tumor-derived DNA can be very small, *e.g.*, 200 or fewer

nucleotides in length. Nucleic acids of this size can be lost during routine purification, due to, *e.g.*, poor binding to purification columns or inefficient alcohol precipitation.

Analysis of such nucleic acids from such samples is especially difficult if multiple targets or loci in the nucleic acid(s) need to be detected. For example, a collected specimen having small numbers of copies of the targets of interest often cannot be divided into a sufficient number of aliquots to permit testing for all targets without risking the accuracy of the tests for the individual targets, *e.g.*, by false negative results.

Pre-amplification of target nucleic acids (*e.g.*, genomic DNA, cDNA, *etc.*) in a low-target sample may be used to enrich the DNA in the sample prior to dividing the sample for further specific target analysis. For example, whole genome amplification using simple primers (*e.g.*, random hexamers) has been used to increase the amounts of essentially all DNA in a sample, in a manner that is not specific to any particular target of interest. (Sigma-Aldrich's GenomePlex systems, Arneson, et al., Cold Spring Harb. Protoc.; 2008; doi:10.1101/pdb.prot4920).

Another approach is to amplify one or more regions of particular interest in a semi-targeted manner, to produce a mixture of amplified fragments (amplicons) that contains the different mutations or loci that will be further analyzed. Successive rounds of amplification using the same primers are prone to high background of non-specific amplification, and the production of artifacts, *e.g.*, artificially recombined molecules, high non-specific background, and biased amplification of different intended targets. Thus, such pre-amplification PCR is typically carried out under special conditions *e.g.*, a limited number of cycles, and/or using a low concentration of primers (*e.g.*, 10 to 20-fold lower than in standard PCR) to avoid increases in non-specific background amplification, as use of concentrations over about 160 nM of each primer in multiplex pre-amplification has been shown to increase amplification background in negative control reactions (see, *e.g.*, Andersson, et al., Expert Rev. Mol. Diagn. Early online, 1–16 (2015)).

After a first round of amplification in a multiplex PCR, pre-amplified DNA is typically diluted and aliquoted into new amplification reactions for quantitative or qualitative PCR analysis using conditions typical of standard PCR, *e.g.*, higher concentrations of reagents and larger numbers of cycles, and the second amplification is generally carried out using different primer pairs, *e.g.*, “nested” primers that anneal to sites within the pre-amplified fragments, rather than annealing to the original primer sites at the ends of the amplicons.

When DNA is to be examined for methylation, the analysis is further complicated by the fact that commonly used processes for preparing samples for methylation detection typically result in substantial losses of sample DNA. For example, bisulfite treatment is typically used to convert unmethylated cytosine residues to uracil residues, but the process typically results in only about 30% recovery of the input DNA. In addition, amplification of DNA after treatment with bisulfite is especially challenging. For example, the conversion of unmethylated cytosines reduces the complexity of the DNA sequences and the treatment itself is known to cause significant damage to the DNA, *e.g.*, strand breakage, both of which can contribute to increased background in amplification reactions, especially in multiplexed amplifications.

SUMMARY

In the course of development of methods described herein, it has been determined that bisulfite-treated DNA from low-target samples can be pre-amplified and amplified for real-time detection without the need for whole-genome pre-amplification and without the use of nested or semi-nested primers. Surprisingly, the targeted pre-amplification can be multiplexed using a combination of the same primer pairs that will be used in a second round of amplification of individual target loci, *e.g.*, in a quantitative allele-specific real-time target and signal amplification (QuARTS) assay (see, *e.g.*, US Pat. Nos. 8,361,720, 8,715,937 and 8,916,344), which combines PCR target amplification and FEN-1-mediated flap cleavage for signal amplification.

In some embodiments, the technology provides a method of analyzing samples such that a plurality of different targets that are present in low copy number may be individually detected with reduced risk of false negative results due to sample splitting. For example, in some embodiments, the technology provides a method of analyzing a sample for multiple target nucleic acids, comprising:

- a) providing a sample having volume x , the sample comprising bisulfite-treated DNA suspected of containing one or more of a plurality of n different target regions, wherein at least one of said target regions is a low-copy target that, if present in said sample, is present in said sample at a copy number such that:
 - i) among n fractions of said sample each having a volume of x/n , said low copy target is absent from one or more of said n fractions, or

- ii) among n fractions of said sample each having a volume of x/n , said low copy target in one or more of said n fractions is below a level of sensitivity of a detection assay for said low copy target;
- b) treating said volume x of said sample to an amplification reaction under conditions wherein said n different target regions, if present in said sample, are amplified to form a pre-amplified mixture having volume y ;
- c) partitioning said pre-amplified mixture into a plurality of different detection assay reaction mixtures, wherein each detection assay reaction mixture comprises a portion of said pre-amplified mixture that has a volume of y/n or less, and wherein said low-copy target, if present in said sample at step a), is present in each of said detection assay reaction mixtures; and
- d) conducting a plurality of detection assays with said detection assay reaction mixtures, wherein said different target regions, if present in said sample at step a), are detected in said detection assay reaction mixtures.

In some embodiments, the bisulfite treated DNA is from a human subject. In certain preferred embodiments, the sample is prepared from a body fluid of a subject, preferably a body fluid comprising plasma. In some embodiments, the bisulfite treated DNA is circulating cell-free DNA (cfDNA) isolated from plasma, *e.g.*, cell-free DNA of less than 200 base pairs in length. In particularly preferred embodiments, cell-free DNA is isolated from plasma by a method comprising combining the plasma sample with a protease (*e.g.*, Pronase, proteinase K) and a first lysis reagent that comprises guanidine thiocyanate and non-ionic detergent to form a mixture in which proteins are digested by the protease, then adding silica particles and a second lysis reagent, with the second lysis reagent comprising a mixture of guanidine thiocyanate, non-ionic detergent, and isopropyl alcohol, under conditions in which DNA is bound to the silica particles. In certain embodiments, the non-ionic detergents in the first lysis reagent and the second lysis reagent are the same or different, and are selected from, *e.g.*, polyethylene glycol sorbitan monolaurate (Tween-20), octylphenoxypolyethoxyethanol (Nonidet P-40), and octylphenoxy poly(ethyleneoxy) ethanol, branched (IGEPAL CA-630).

The method further comprises separating the silica particle with bound DNA from the mixture, washing the separated silica particles with bound DNA with a first wash solution comprising guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol, separating the silica particles with bound DNA from the first wash solution and washing the silica

particles with bound DNA with a second wash solution comprising a buffer, *e.g.*, Tris pH 8.0 and ethyl alcohol. In preferred embodiments, the silica particles with bound DNA are washed multiple times, *e.g.*, 2 to 6 times, with the second wash buffer. In particularly preferred embodiments, each wash uses a smaller volume of the second wash buffer than the prior wash with that buffer. In some embodiments the washed silica particles are separated from the last wash buffer treatment and the DNA is eluted from the silica particles, *e.g.*, with an elution buffer, such as 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA. In preferred embodiments, the silica particles with bound DNA are dried, *e.g.*, by heating to about 70°C, prior to elution of the DNA.

The technology is not limited to any particular sample size, but it finds particular application in samples in which low-copy targets are present in large samples. For example, in some embodiments, the bisulfite treated DNA is prepared from a body fluid, *e.g.*, a plasma sample, having a starting volume of at least one mL, preferably at least 5 mL, more preferably at least 10 mL, and/or wherein said volume *x* of the sample of bisulfite treated DNA is at least 10µl, preferably at least 25 µl, more preferably at least 50µl, more preferably at least 100 µl. In preferred embodiments, the volume of treated DNA sample that is present in the pre-amplification reaction is at least 5%, preferably at least 10%-60%, preferably 15%-55%, more preferably about 20% - 50% of the total volume of the amplification reaction.

The invention is not limited to a particular number of fractions into which the sample is divided. In some embodiments, *n* (the number of fractions) is at least 3, preferably at least 5, more preferably at least 10, more preferably at least 20, more preferably at least 100.

In some embodiments, the technology provides a method for analyzing multiple target nucleic acids in a sample using a PCR pre-amplification and a PCR-flap assay, the method comprising:

- a) providing bisulfite-treated DNA (in preferred embodiments, comprising human DNA) comprising a plurality of different target regions in a first reaction mixture comprising PCR amplification reagents, wherein said PCR amplification reagents comprise:
 - i) a plurality of different primer pairs for amplifying said plurality of different target regions, if present in said sample, from said bisulfite-treated DNA;
 - ii) thermostable DNA polymerase;
 - iii) dNTPs; and
 - iv) a buffer comprising Mg^{++}

- b) exposing said first reaction mixture to thermal cycling conditions wherein a plurality of different target regions, if present in the sample, are amplified to produce a pre-amplified mixture, and wherein said thermal cycling conditions are limited to a number of thermal cycles that maintain amplification in an exponential range, preferably fewer than 20, more preferably fewer than 15, more preferably 10 or fewer thermal cycles;
- c) partitioning said pre-amplified mixture into a plurality of PCR-flap assay reaction mixtures, wherein each PCR-flap assay reaction mixture comprises:
 - i) an additional amount of a primer pair selected from said plurality of different primer pairs of step a) i);
 - ii) thermostable DNA polymerase;
 - iii) dNTPs;
 - iv) said buffer comprising Mg^{++}
 - v) a flap endonuclease, preferably a FEN-1 endonuclease;
 - vi) a flap oligonucleotide, and
 - vi) a hairpin oligonucleotide comprising a region that is complimentary to a portion of said flap oligonucleotide, preferably a FRET cassette oligonucleotide;

and

- d) detecting amplification of one or more different target regions from said bisulfite-treated DNA during PCR-flap assay reactions by detecting cleavage of said hairpin oligonucleotide by said flap endonuclease.

In preferred embodiments, the FEN-1 endonuclease is a thermostable FEN-1, preferably from an archaeal organism, *e.g.*, Afu FEN-1.

In some embodiments, the pre-amplified mixtures described above are diluted with a diluent prior to partitioning into PCR-flap assay reaction mixtures, while in some embodiments, the pre-amplified mixture is added directly to a PCR-flap assay reaction mixture without prior dilution.

In some embodiments, essentially the primers used in the PCR-flap assay reaction are used at the same concentrations at which those particular primers were used in the first

reaction mixture, excluding any primers carried over from the first reaction. For example, in some embodiments, the primers in the additional amount of a primer pair added to the PCR-flap assay reaction mixture are added to a concentration such that the concentration of the *added* primers in the PCR-flap assay (*i.e.*, not counting primers coming from the pre-amplified mixture) is essentially the same as the concentration of the primers of that primer pair in said PCR amplification reagents. In other embodiments, the primers in the additional amount of a primer pair added to the PCR-flap assay reaction mixture are added to a concentration such that the concentration of the *added* primers in the PCR-flap assay are at a lower or a higher concentration than the concentration of the primers of that primer pair in the first reaction mixture.

While the method is not limited to a particular concentration of Mg^{++} in the buffer used in said first reaction mixture and in the PCR-flap assay reaction mixture, in preferred embodiments, the buffer comprises at least 3 mM Mg^{++} , preferably greater than 4 mM Mg^{++} , more preferably greater than 5 mM Mg^{++} , more preferably greater than 6 mM Mg^{++} , more preferably between approximately 7 mM and 7.5 mM Mg^{++} . In certain embodiments, the buffer contains less than about 1mM KCl. In preferred embodiments, the buffer comprises 10 mM 3-(n-morpholino) propanesulfonic acid (MOPS) buffer and 7.5 mM $MgCl_2$.

In some embodiments, the first reaction mixture and/or said plurality of PCR-flap assay reaction mixtures comprise exogenous non-target DNA, preferably bulk fish DNA.

In some embodiments, the thermostable DNA polymerase is a eubacterial DNA polymerase, preferably from genus *Thermus*, more preferably from *Thermus aquaticus*. In some embodiments, the DNA polymerase is modified for hot start PCR, *e.g.*, through the use of a reagent, *e.g.*, an antibody, chemical adduct, *etc.*, such that the DNA polymerase is activated upon heating.

In certain embodiments, the bisulfite-treated DNA comprises human DNA, and the plurality of different target regions comprises target regions selected from the group consisting of SFMBT2, VAV3, BMP3, and NDRG4. In some embodiments, a plurality of different primer pairs are directed to at least two, preferably at least three, more preferably all four of these target regions.

In some embodiments, the plurality of different target regions comprise a reference target region, and in certain preferred embodiments, the reference target region comprises β -actin and and/or ZDHHC1, and/or B3GALT6.

In some embodiments, at least one of the plurality of different primer pairs is selected to produce an amplicon from a target region that is less than about 100 base pairs long,

preferably less than about 85 base pairs long. In certain preferred embodiments, all of the different primer pairs are selected to produce an amplicon from a target region that is less than about 100 base pairs long.

In some embodiments, methods provided herein are directed to amplifying substantially all of the bisulfite-treated DNA produced during the process of a sample, *e.g.*, a sample of bodily fluid. In some embodiments, the preparation of bisulfite treated DNA constitutes a substantial fraction of the first reaction mixtures, *e.g.*, in some embodiments, the volume of the sample comprising bisulfite-treated DNA in the first reaction mixture constitutes at least 20- 50% of the total volume of the first reaction mixture. For example, in some embodiments, the volume of bisulfite-treated DNA in the first reaction mixture is at least 5%, preferably at least 10%-60%, preferably 15%-55%, more preferably between about 20% - 50% of the total volume of the first reaction mixture.

In some embodiments, methods of the technology provide a method for analyzing multiple target nucleic acids in a sample of human plasma using a PCR pre-amplification and a PCR-flap assay, the method comprising:

- a) providing bisulfite-treated DNA prepared from at least 1 mL of plasma, the bisulfite treated DNA comprising a plurality of different target regions in a first reaction mixture comprising PCR amplification reagents, wherein said PCR amplification reagents comprise:
 - i) a plurality of different primer pairs for amplifying said plurality of different target regions, said target regions selected from SFMBT2, VAV3, BMP3, and NDRG4, if present in said sample, from said bisulfite-treated DNA, wherein each of said plurality of different primer pairs is selected to produce an amplicon from a target region that is less than about 100 base pairs long;
 - ii) DNA polymerase from *Thermus aquaticus*;
 - iii) dNTPs; and
 - iv) a buffer comprising 7.5 mM Mg⁺⁺
- b) exposing said first reaction mixture to thermal cycling conditions wherein a plurality of different target regions, if present in the sample, are amplified to produce a pre-amplified mixture, and wherein said thermal cycling conditions

are limited to a number of thermal cycles that maintain amplification in an exponential range, preferably fewer than 20, more preferably fewer than 15, more preferably 10 or fewer thermal cycles;

- c) partitioning said pre-amplified mixture into a plurality of PCR-flap assay reaction mixtures, wherein each PCR-flap assay reaction mixture comprises:
 - i) an additional amount of a primer pair selected from said plurality of different primer pairs of step a) i);
 - ii) DNA polymerase from *Thermus aquaticus*;
 - iii) dNTPs;
 - iv) said buffer comprising 7.5 mM Mg⁺⁺
 - v) a thermostable FEN-1 flap endonuclease;
 - vi) a flap oligonucleotide, and
 - vi) a FRET cassette oligonucleotide comprising a region that is complimentary to a portion of said flap oligonucleotide;

and

- d) detecting amplification of one or more the different target regions selected from SFMBT2, VAV3, BMP3, and NDRG4 during PCR-flap assay reactions.

In preferred embodiments, the plurality of different target regions comprise a reference target region, preferably comprising comprises β -actin and/or ZDHHC1. In certain embodiments, one or more of the target regions and/or primers pairs is selected from the target regions and primer pairs depicted in Figures 5A-5F.

Also provided herein are improved methods for isolating DNA, *e.g.*, cell-free DNA from blood or blood fractions, *e.g.*, plasma or serum. For example, embodiments provide methods of processing a plasma sample, the method comprising combining the plasma sample with a protease and a first lysis reagent that comprises guanidine thiocyanate and non-ionic detergent to form a mixture in which proteins are digested by the protease, then adding mixable silica particles and a second lysis reagent, with the second lysis reagent comprising a mixture of guanidine thiocyanate, non-ionic detergent, and isopropyl alcohol, under conditions in which DNA is bound to the silica particles. In certain embodiments, the non-ionic detergents in the first lysis reagent and the second lysis reagent are the same or different, and are selected from, *e.g.*, polyethylene glycol sorbitan monolaurate (Tween-20),

octylphenoxypolyethoxyethanol (Nonidet P-40), and octylphenoxy poly(ethyleneoxy) ethanol, branched (IGEPAL CA-630). In certain preferred embodiments, the silica particles are magnetic particles.

The method further comprises separating the silica particles with bound DNA from the mixture, washing the separated silica particles with bound DNA with a first wash solution comprising guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol, separating the silica particles with bound DNA from the first wash solution and washing the silica particles with bound DNA with a second wash solution comprising a buffer, *e.g.*, Tris pH 8.0, and ethyl alcohol. In preferred embodiments, the silica particles with bound DNA are washed multiple times, *e.g.*, 2 to 6 times, with the second wash buffer. In particularly preferred embodiments, each wash uses a smaller volume of the second wash buffer than the prior wash with that buffer. In some embodiments the washed silica particles are separated from the last wash buffer treatment and the DNA is eluted from the silica particles, *e.g.*, with water or with an elution buffer, such as 10 mM Tris-HCl pH 8.0, 0.1 mM EDTA. In preferred embodiments, the silica particles with bound DNA are dried after the last wash step, *e.g.*, by heating (to, for example, 37°C to 75°C, preferably about 45°C to 70°C, more preferably about 70°C), prior to elution of the DNA.

During development of the technology it was discovered that use two different lysis reagents, added at different times in the procedure, improves yield of DNA from plasma. In preferred embodiments, an aliquot of the second lysis reagent is added after the mixture comprising the first lysis reagent and protease have incubated, *e.g.*, for about 5 to 60 minutes, preferably 30 to 60 minutes, at room temperature to 55°C. In preferred embodiments, the mixture is incubated at room temperature. In certain embodiments, the first lysis reagent comprises guanidine thiocyanate and a non-ionic detergent, and the second lysis reagent comprises guanidine thiocyanate, a non-ionic detergent, and an alcohol. In preferred embodiments, the first lysis reagent comprises about 4.3 M guanidine thiocyanate and 10% w:v IGEPAL CA-630, and in some embodiments, the second lysis reagent comprises 4.3 M guanidine thiocyanate and 10% w:v IGEPAL CA-630 combined with isopropyl alcohol.

During development of the technology it was discovered that use two different wash solutions at different steps in the procedure improved yield of DNA from plasma. In some embodiments, a first wash solution, used as described above, comprises guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol, and the second wash solution comprises a buffer and ethyl alcohol. In particularly preferred embodiments, the first wash solution comprises about 3 M guanidine hydrochloride or guanidine thiocyanate and about

57% ethyl alcohol and the second wash solution, used as described above, comprises about 80% ethyl alcohol and about 20% 10 mM Tris pH 8.0 buffer.

In particularly preferred embodiments, all lysis steps and wash steps are conducted at room temperature.

In some embodiments, the plasma sample is mixed with a DNA process control, *e.g.*, a DNA that does not cross-react with assays configured to detect DNA found in the plasma sample. For example, in some embodiments the plasma is human plasma and the DNA process control comprises a zebrafish *RASSF1* sequence. In preferred embodiments, the DNA process control is synthetic DNA, *e.g.*, a synthetic DNA fragment comprising a zebrafish *RASSF1* sequence. In particularly preferred embodiments, the DNA process control is double stranded. In preferred embodiments, the process control is added to the plasma sample prior to extraction of DNA from the sample, *e.g.*, along with the first or second lysis reagent additions.

In some embodiments, bulk exogenous DNA, *e.g.*, DNA that does not cross-react with assays configured to detect DNA found in the plasma sample, is added to the plasma sample. For example, in preferred embodiments, the plasma is human plasma and bulk fish DNA, *e.g.*, genomic DNA from salmon, is added to the sample.

Embodiments of the methods provided herein find particular use in the processing of relatively large plasma samples, *e.g.*, greater than 1 mL. In preferred embodiments, the plasma sample has a volume of at least 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or at least 10 mL, or any fractional volume therebetween. In some embodiments the plasma sample is greater than 10 mL in volume.

In some embodiments, the method further comprises analyzing the isolated DNA sample for particular target nucleic acids. In preferred embodiments, the method comprises analyzing the isolated DNA for a plurality of methylated target nucleic acids, the method comprising treating the isolated DNA sample with bisulfite to produce a bisulfite-treated DNA sample, treating the bisulfite-treated DNA sample to an amplification reaction under conditions wherein a plurality of different target regions (*e.g.*, 2, 3, 4, 5, *etc.* target regions), if present in the sample, are amplified to form an amplified mixture.

In certain preferred embodiments the method further comprises partitioning the amplified mixture into a plurality of different detection assay reaction mixtures and conducting a plurality of different detection assays with the detection assay reaction mixtures, wherein the plurality of different target regions, if present in the sample, are detected in one or more of the plurality of different detection assay reaction mixtures. In preferred

embodiments, the plurality of different target regions comprises at least 5 different target regions.

Provided herein are kits and systems for performing methods described herein. In some embodiments the technology provides a kit for isolating DNA from plasma, the kit comprising, *e.g.*:

- a) a first lysis reagent comprising guanidine thiocyanate and a non-ionic detergent or components for preparing the first lysis reagent;
- b) a second lysis reagent comprising guanidine thiocyanate, a non-ionic detergent, and isopropanol, or components for preparing the second lysis reagent;
- c) a first wash solution comprising guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol, or components for preparing the first wash solution;
- d) a second wash solution comprising Tris buffer and ethyl alcohol, or components for preparing the second wash solution; and
- e) silica particles.

In preferred embodiments, the non-ionic detergent comprises IGEPAL CA-630. In some embodiments, the silica particles are magnetic particles, and in particularly preferred embodiments, the kit comprises a magnet, *e.g.*, for separating the particles during steps of the procedure. In some embodiments, the kit further comprises an elution buffer or components for preparing the elution buffer.

In some embodiments the kit further comprises a DNA process control, *e.g.*, a DNA process control comprising a zebrafish *RASSF1* sequence. In some embodiments the kit further comprises a preparation of bulk fish DNA, and in particularly preferred embodiments, the DNA process control is in a preparation of bulk fish DNA.

In some embodiments the technology provides a system for processing a plasma sample, the system comprising:

- a) a first lysis reagent comprising guanidine thiocyanate and a non-ionic detergent or components for preparing the first lysis reagent;
- b) a second lysis reagent comprising guanidine thiocyanate, a non-ionic detergent, and isopropanol, or components for preparing the second lysis reagent;
- c) a first wash solution comprising guanidine hydrochloride or guanidine thiocyanate and ethyl alcohol, or components for preparing the first wash solution;
- d) a second wash solution comprising Tris buffer and ethyl alcohol, or components for preparing the second wash solution; and

- e) silica particles.

In preferred embodiments, the non-ionic detergent comprises IGEPAL CA-630.

In some embodiments the system further comprises an elution buffer or components for preparing said elution buffer.

In some embodiments the system further comprises a DNA process control, *e.g.*, a DNA process control comprising a zebrafish *RASSF1* sequence. In some embodiments the system further comprises a preparation of bulk fish DNA, and in particularly preferred embodiments, the DNA process control is in a preparation of bulk fish DNA.

In some embodiments, the system further comprises one or more of: a magnet, a vessel for processing plasma, and/or a vessel or plate for receiving purified DNA. In some embodiments, the system comprises a device for performing all or part of the steps, *e.g.*, a device such as a STARlet automated platform.

In some embodiments, the system further comprises reagents for analysis of DNA isolated from plasma. For example, in certain embodiments, the system comprises reagents for treating DNA with bisulfite to produce bisulfite-treated DNA, *e.g.*, a bisulfite reagent, a desulfonation reagent, and materials for purifying bisulfite-treated DNA (*e.g.*, silica beads, a binding buffer, a solution comprising bovine serum albumin and/or casein, *e.g.*, as described in U.S. Patent No. 9,315,853).

In preferred embodiments, the system further comprises DNA analysis reagents, *e.g.*, PCR amplification reagents and/or flap assay reagents. In particularly preferred embodiments, the system comprises PCR amplification reagents comprising:

- i) a plurality of different primer pairs for amplifying a plurality of different target regions, if present in said plasma;
- ii) thermostable DNA polymerase;
- iii) dNTPs; and
- iv) a buffer comprising Mg^{++}

In some embodiments, the system further comprises PCR-flap assay reagents. In certain preferred embodiments, the PCR flap assay reagents comprise:

- i) a plurality of different primer pairs for amplifying a plurality of different target regions, if present in said plasma;
- ii) thermostable DNA polymerase;

- iii) dNTPs;
- iv) a buffer comprising Mg^{++}
- v) a flap endonuclease;
- vi) a flap oligonucleotide, and
- vi) a hairpin oligonucleotide comprising a region that is complimentary to a portion of said flap oligonucleotide.

In still further embodiments, the system comprises a thermal cycler for conducting PCR amplification and/or PCR flap assay reactions. In preferred embodiments, the thermal cycler is configured to detect signal, *e.g.*, fluorescence, during the course of amplification reactions conducted with the assay reagents.

Additional embodiments will be apparent to persons skilled in the relevant art based on the teachings contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the present technology will become better understood with regard to the following drawings:

Figure 1 provides a schematic diagram of a combined PCR- invasive cleavage assay (“PCR-flap assay”), *e.g.*, a QuARTS assay.

Figure 2 provides a schematic diagram of nested PCR combined with a PCR-flap assay, showing a first amplification (or pre-amplification) using outer primers, followed by a PCR-flap assay using a second pair of primers having binding sites within the sites of the outer primers. The smaller amplicon produced in the second amplification is shown at the bottom. The FRET-cassette portion of the reaction is not shown.

Figure 3 provides a schematic diagram of a PCR pre-amplification followed by a PCR-flap assay in which the pre-amplification and the PCR-flap assay use the same primer pair, and producing copies of the same amplicon. The FRET-cassette portion of the reaction is not shown.

Figure 4 provides a schematic diagram of a multiplex pre-amplification in which a plurality of different target regions in a sample are amplified in a single multiplexed PCR reaction containing primer pairs for each of the different target regions, followed by individual PCR-flap assay reactions in which each PCR flap assay uses only the primer pair specific for the target locus to be detected in the final PCR-flap assay reaction.

Figures 5A- 5F show nucleic acid sequences for analysis of methylation using the combination of bisulfite conversion, pre-amplification, and PCR-flap assay detection. Each panel shows one strand of the DNA target region prior to bisulfite treatment and the expected sequence of that region upon conversion with bisulfite reagent, with converted unmethylated C residues shown as 'T's. The primer binding sites for outer primers and for PCR-flap assay inner primers (as would be used for a nested assay design) are shown boxed. Each figure also shows an alignment of the PCR-flap assay primers and flap probe on a segment of the converted sequence. Figures 5A-5F show target regions of markers SFMBT2, VAV3, BMP3, NDRG4, and reference DNAs β -actin, and ZDHHC1, respectively. The 'arms' on the flap oligonucleotides used in the PCR-flap assay are as follows: Arm 1 is 5'-CGCCGAGG-3'; Arm 3 is 5'-GACGCGGAG-3'; and Arm 5 is 5'-CCACGGACG-3'.

Figure 6 shows a table comparing detection of the indicated bisulfite-treated target DNAs pre-amplified using outer primers for different numbers of cycles, followed by PCR-flap assay amplification and detection using nested (inner) primers. Comparative assays used a QuARTS PCR-flap assay directly on the bisulfite-treated DNA, without pre-amplification.

Figure 7 compares results using nested or non-nested amplification primer configurations as shown in Figures 5A-5F, and compares different primer concentrations and different buffers in the PCR pre-amplification step, as described in Example 3.

Figures 8A-8C show the results of using different numbers of cycles in the pre-amplification phase of the assay. Figure 8A shows the number of strands expected for each of the target types in normal plasma samples or in plasma samples spiked with known amounts of target DNAs, with either no pre-amplification, or with 5, 10, 20 or 25 cycles of amplification. Figure 8B compares the number of strands detection in each reaction under the conditions show, as described in Example 4.

Figure 9 shows the results of using a non-nested multiplex pre-amplification on DNA isolated from stool, as described in Example 5.

Figures 10A-10I. show the results of using a non-nested multiplex pre-amplification on DNA isolated from plasma, as described in Example 6.

Figures 11A-11C show graphs comparing different plasma isolation conditions on the yield of β -actin DNA (untreated and bisulfite converted after extraction) and the B3GALT6 gene (bisulfite converted after extraction, as described in Example 8.

Figures 12A-12-C show graphs comparing different plasma isolation conditions on the yield of β -actin DNA (untreated and bisulfite converted after extraction) and the B3GALT6 gene (bisulfite converted after extraction, as described in Example 10.

Figure 13 shows a table of nucleic acid sequences relating to embodiments herein.

It is to be understood that the figures are not necessarily drawn to scale, nor are the objects in the figures necessarily drawn to scale in relationship to one another. The figures are depictions that are intended to bring clarity and understanding to various embodiments of apparatuses, systems, and methods disclosed herein. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. Moreover, it should be appreciated that the drawings are not intended to limit the scope of the present teachings in any way.

DEFINITIONS

To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.

Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the technology may be readily combined, without departing from the scope or spirit of the technology.

In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”

The transitional phrase “consisting essentially of” as used in claims in the present application limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention, as discussed in *In re Herz*, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976). For example, a composition “consisting essentially of” recited elements may contain an unrecited contaminant at a level such that, though present, the contaminant does not alter the function of the recited composition as compared to a pure composition, *i.e.*, a composition “consisting of” the recited components.

As used herein in reference to non-target DNA, the term “exogenous” refers to non-target DNA that is isolated and purified from a source other than the source or sample containing the target DNA. For example, purified fish DNA is exogenous DNA with respect to a sample comprising human target DNA, *e.g.*, as described in U.S. Patent No.9,212,392. Exogenous DNA need not be from a different organism than the target DNA. For example, purified fish DNA obtained commercially would be exogenous if added to a reaction configured to detect a target nucleic acid in a sample from a particular fish. In preferred embodiments, exogenous DNA is selected to be undetected by an assay configured to detect and/or quantify the target nucleic acid in the reaction in to which the exogenous DNA is added.

As used herein, a “DNA fragment” or “small DNA” or “short DNA” means a DNA that consists of no more than approximately 200 base pairs or nucleotides in length.

The term “primer” refers to an oligonucleotide that is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide “primer” may occur naturally, as in a purified restriction digest or may be produced synthetically. In some embodiments, an oligonucleotide primer is used with a template nucleic acid and extension of the primer is template dependent, such that a complement of the template is formed.

The term “amplifying” or “amplification” in the context of nucleic acids refers to the production of multiple copies of a polynucleotide, or a portion of the polynucleotide, typically starting from a small amount of the polynucleotide (*e.g.*, a single polynucleotide molecule), where the amplification products or amplicons are generally detectable. Amplification of polynucleotides encompasses a variety of chemical and enzymatic processes. The generation of multiple DNA copies from one or a few copies of a target or template DNA molecule during a polymerase chain reaction (PCR) or a ligase chain reaction (LCR; see, *e.g.*, U.S. Patent No. 5,494,810) are forms of amplification. Additional types of amplification include, but are not limited to, allele-specific PCR (see, *e.g.*, U.S. Patent No. 5,639,611), assembly PCR (see, *e.g.*, U.S. Patent No. 5,965,408), helicase-dependent amplification (see, *e.g.*, U.S. Patent No. 7,662,594), hot-start PCR (see, *e.g.*, U.S. Patent Nos. 5,773,258 and 5,338,671), intersequence-specific PCR, inverse PCR (see, *e.g.*, Triglia, *et al.*, (1988) *Nucleic Acids Res.*, 16:8186), ligation-mediated PCR (see, *e.g.*, Guilfoyle, R. *et al.*, *Nucleic Acids Research*, 25:1854-1858 (1997); U.S. Patent No. 5,508,169), methylation-specific PCR (see, *e.g.*, Herman, *et al.*, (1996) *PNAS* 93(13) 9821-9826), miniprimer PCR, multiplex ligation-dependent probe amplification (see, *e.g.*, Schouten, *et al.*, (2002) *Nucleic*

Acids Research 30(12): e57), multiplex PCR (see, *e.g.*, Chamberlain, *et al.*, (1988) Nucleic Acids Research 16(23) 11141-11156; Ballabio, *et al.*, (1990) Human Genetics 84(6) 571-573; Hayden, *et al.*, (2008) BMC Genetics 9:80), nested PCR, overlap-extension PCR (see, *e.g.*, Higuchi, *et al.*, (1988) Nucleic Acids Research 16(15) 7351-7367), real time PCR (see, *e.g.*, Higuchi, *et al.*, (1992) Biotechnology 10:413-417; Higuchi, *et al.*, (1993) Biotechnology 11:1026-1030), reverse transcription PCR (see, *e.g.*, Bustin, S.A. (2000) J. Molecular Endocrinology 25:169-193), solid phase PCR, thermal asymmetric interlaced PCR, and Touchdown PCR (see, *e.g.*, Don, *et al.*, Nucleic Acids Research (1991) 19(14) 4008; Roux, K. (1994) Biotechniques 16(5) 812-814; Hecker, *et al.*, (1996) Biotechniques 20(3) 478-485). Polynucleotide amplification also can be accomplished using digital PCR (see, *e.g.*, Kalinina, *et al.*, Nucleic Acids Research. 25; 1999-2004, (1997); Vogelstein and Kinzler, Proc Natl Acad Sci USA. 96; 9236-41, (1999); International Patent Publication No. WO05023091A2; US Patent Application Publication No. 20070202525).

The term “polymerase chain reaction” (“PCR”) refers to the method of K.B. Mullis U.S. Patent Nos. 4,683,195, 4,683,202, and 4,965,188, that describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic or other DNA or RNA, without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the “polymerase chain reaction” (“PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified” and are “PCR products” or “amplicons.” Those of skill in the art will understand the term “PCR” encompasses many variants of the originally described method using, *e.g.*, real time PCR,

nested PCR, reverse transcription PCR (RT-PCR), single primer and arbitrarily primed PCR, *etc.*

As used herein, the term “nucleic acid detection assay” refers to any method of determining the nucleotide composition of a nucleic acid of interest. Nucleic acid detection assay include but are not limited to, DNA sequencing methods, probe hybridization methods, structure specific cleavage assays (*e.g.*, the “INVADER” flap assay, or invasive cleavage assay, (Hologic, Inc.) described, *e.g.*, in U.S. Patent Nos. 5,846,717, 5,985,557, 5,994,069, 6,001,567, 6,090,543, and 6,872,816; Lyamichev et al., Nat. Biotech., 17:292 (1999), Hall et al., PNAS, USA, 97:8272 (2000), and in combined PCR/invasive cleavage assays (Hologic, Inc., *e.g.*, in U.S. Patent Publications 2006/0147955 and 2009/0253142); enzyme mismatch cleavage methods (*e.g.*, Variagenics, U.S. Pat. Nos. 6,110,684, 5,958,692, 5,851,770); polymerase chain reaction (PCR), described above; branched hybridization methods (*e.g.*, Chiron, U.S. Pat. Nos. 5,849,481, 5,710,264, 5,124,246, and 5,624,802); rolling circle replication (*e.g.*, U.S. Pat. Nos. 6,210,884, 6,183,960 and 6,235,502); NASBA (*e.g.*, U.S. Pat. No. 5,409,818); molecular beacon technology (*e.g.*, U.S. Pat. No. 6,150,097, herein); E-sensor technology (U.S. Pat. Nos. 6,248,229 6,221,583, 6,013,170, and 6,063,573); cycling probe technology (*e.g.*, U.S. Pat. Nos. 5,403,711, 5,011,769, and 5,660,988); Dade Behring signal amplification methods (*e.g.*, U.S. Pat. Nos. 6,121,001, 6,110,677, 5,914,230, 5,882,867, and 5,792,614); ligase chain reaction (*e.g.*, Barany Proc. Natl. Acad. Sci USA 88, 189-93 (1991)); and sandwich hybridization methods (*e.g.*, U.S. Pat. No. 5,288,609).

In some embodiments, target nucleic acid is amplified (*e.g.*, by PCR) and amplified nucleic acid is detected simultaneously using an invasive cleavage assay. Assays configured for performing a detection assay (*e.g.*, invasive cleavage assay) in combination with an amplification assay are described in US Patent Publication 20090253142 A1 (App. Ser. No. 12/404,240), and as diagrammed in Figure 1. Because many copies of the FRET cassette are cleaved for each copy of the target amplicon produced, the assay is said to produce “signal amplification” in addition to target amplification. Additional amplification plus invasive cleavage detection configurations, termed the QuARTS method, are described in U.S. Pat. No. 8,361,720, 8,715,937, and 8,916,344.

As used herein, the term “PCR-flap assay” is used interchangeably with the term “PCR-invasive cleavage assay” and refers to an assay configuration combining PCR target amplification and detection of the amplified DNA by formation of a first overlap cleavage structure comprising amplified target DNA, and a second overlap cleavage structure

comprising a cleaved 5' flap from the first overlap cleavage structure and a labeled hairpin detection oligonucleotide called a "FRET cassette". In the PCR-flap assay as used herein, the assay reagents comprise a mixture containing DNA polymerase, FEN-1 endonuclease, a primary probe comprising a portion complementary to a target nucleic acid, and a hairpin FRET cassette, and the target nucleic acid is amplified by PCR and the amplified nucleic acid is detected simultaneously (*i.e.*, detection occurs during the course of target amplification). PCR-flap assays include the QuARTS assays described in U.S. Pat. Nos. 8,361,720; 8,715,937; and 8,916,344, and the amplification assays of US Pat. No. 9,096,893 (for example, as diagrammed in Figure 1 of that patent).

As used herein, the term "PCR-flap assay reagents" refers to one or more reagents for detecting target sequences in a PCR-flap assay, the reagents comprising nucleic acid molecules capable of participating in amplification of a target nucleic acid and in formation of a flap cleavage structure in the presence of the target sequence, in a mixture containing DNA polymerase, FEN-1 endonuclease and a FRET cassette.

As used herein, the term "flap assay reagents" or "invasive cleavage assay reagents" refers to all reagents that are required for performing a flap assay or invasive cleavage assay on a substrate. As is known in the art, flap assays generally include an invasive oligonucleotide, a flap oligonucleotide, a flap endonuclease and, optionally, a FRET cassette, as described above. Flap assay reagents may optionally contain a target to which the invasive oligonucleotide and flap oligonucleotide bind.

As used herein, the term "flap oligonucleotide" refers to an oligonucleotide cleavable in a detection assay, such as an invasive cleavage assay, by a flap endonuclease. In preferred embodiments, a flap oligonucleotide forms an invasive cleavage structure with other nucleic acids, *e.g.*, a target nucleic acid and an invasive oligonucleotide.

As used herein, the term "FRET cassette" refers to a hairpin oligonucleotide that contains a fluorophore moiety and a nearby quencher moiety that quenches the fluorophore. Hybridization of a cleaved flap (*e.g.*, from cleavage of a target-specific probe in a PCR-flap assay) with a FRET cassette produces a secondary substrate for the flap endonuclease, *e.g.*, a FEN-1 enzyme. Once this substrate is formed, the 5' fluorophore-containing base is cleaved from the cassette, thereby generating a fluorescence signal. In preferred embodiments, a FRET cassette comprises an unpaired 3' portion to which a cleavage product, *e.g.*, a portion of a cleaved flap oligonucleotide, can hybridize to form an invasive cleavage structure cleavable by a FEN-1 endonuclease.

A nucleic acid “hairpin” as used herein refers to a region of a single-stranded nucleic acid that contains a duplex (*i.e.*, base-paired) stem and a loop, formed when the nucleic acid comprises two portions that are sufficiently complementary to each other to form a plurality of consecutive base pairs.

As used herein, the term “FRET” refers to fluorescence resonance energy transfer, a process in which moieties (*e.g.*, fluorophores) transfer energy *e.g.*, among themselves, or, from a fluorophore to a non-fluorophore (*e.g.*, a quencher molecule). In some circumstances, FRET involves an excited donor fluorophore transferring energy to a lower-energy acceptor fluorophore via a short-range (*e.g.*, about 10 nm or less) dipole-dipole interaction. In other circumstances, FRET involves a loss of fluorescence energy from a donor and an increase in fluorescence in an acceptor fluorophore. In still other forms of FRET, energy can be exchanged from an excited donor fluorophore to a non-fluorescing molecule (*e.g.*, a quenching molecule). FRET is known to those of skill in the art and has been described (See, *e.g.*, Stryer et al., 1978, *Ann. Rev. Biochem.*, 47:819; Selvin, 1995, *Methods Enzymol.*, 246:300; Orpana, 2004 *Biomol Eng* 21, 45-50; Olivier, 2005 *Mutant Res* 573, 103-110).

As used herein, the term “FEN-1” in reference to an enzyme refers to a non-polymerase flap endonuclease from a eukaryote or archaeal organism, as encoded by a FEN-1 gene. See, *e.g.*, WO 02/070755, and Kaiser M.W., et al. (1999) *J. Biol. Chem.*, 274:21387.

As used herein, the term “FEN-1 activity” refers to any enzymatic activity of a FEN-1 enzyme.

As used herein, the term “primer annealing” refers to conditions that permit oligonucleotide primers to hybridize to template nucleic acid strands. Conditions for primer annealing vary with the length and sequence of the primer and are generally based upon the T_m that is determined or calculated for the primer. For example, an annealing step in an amplification method that involves thermocycling involves reducing the temperature after a heat denaturation step to a temperature based on the T_m of the primer sequence, for a time sufficient to permit such annealing.

As used herein, the term “amplifiable nucleic acid” is used in reference to nucleic acids that may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” will usually comprise “sample template.”

The term “real time” as used herein in reference to detection of nucleic acid amplification or signal amplification refers to the detection or measurement of the accumulation of products or signal in the reaction while the reaction is in progress, *e.g.*, during incubation or thermal cycling. Such detection or measurement may occur

continuously, or it may occur at a plurality of discrete points during the progress of the amplification reaction, or it may be a combination. For example, in a polymerase chain reaction, detection (*e.g.*, of fluorescence) may occur continuously during all or part of thermal cycling, or it may occur transiently, at one or more points during one or more cycles. In some embodiments, real time detection of PCR is accomplished by determining a level of fluorescence at the same point (*e.g.*, a time point in the cycle, or temperature step in the cycle) in each of a plurality of cycles, or in every cycle. Real time detection of amplification may also be referred to as detection “during” the amplification reaction.

As used herein, the term “abundance of nucleic acid” refers to the amount of a particular target nucleic acid sequence present in a sample or aliquot. The amount is generally referred to in terms of mass (*e.g.*, μg), mass per unit of volume (*e.g.*, $\mu\text{g}/\mu\text{L}$); copy number (*e.g.*, 1000 copies, 1 attomole), or copy number per unit of volume (*e.g.*, 1000 copies per mL, 1 attomole per μL). Abundance of a nucleic acid can also be expressed as an amount relative to the amount of a standard of known concentration or copy number. Measurement of abundance of a nucleic acid may be on any basis understood by those of skill in the art as being a suitable quantitative representation of nucleic acid abundance, including physical density or the sample, optical density, refractive property, staining properties, or on the basis of the intensity of a detectable label, *e.g.* a fluorescent label.

The term “amplicon” or “amplified product” refers to a segment of nucleic acid, generally DNA, generated by an amplification process such as the PCR process. The terms are also used in reference to RNA segments produced by amplification methods that employ RNA polymerases, such as NASBA, TMA, *etc.*

The term “amplification plot” as used in reference to a thermal cycling amplification reaction refers to the plot of signal that is indicative of amplification, *e.g.*, fluorescence signal, versus cycle number. When used in reference to a non-thermal cycling amplification method, an amplification plot generally refers to a plot of the accumulation of signal as a function of time.

The term “baseline” as used in reference to an amplification plot refers to the detected signal coming from assembled amplification reactions prior to incubation or, in the case of PCR, in the initial cycles, in which there is little change in signal.

The term “ C_t ” or “threshold cycle” as used herein in reference to real time detection during an amplification reaction that is thermal cycled refers to the fractional cycle number at which the detected signal (*e.g.*, fluorescence) passes the fixed threshold.

The term “no template control” and “no target control” (or “NTC”) as used herein in reference to a control reaction refers to a reaction or sample that does not contain template or target nucleic acid. It is used to verify amplification quality.

As used herein, the term “sample template” refers to nucleic acid originating from a sample that is analyzed for the presence of “target.” In contrast, “background template” is used in reference to nucleic acid other than sample template that may or may not be present in a sample. The presence of background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.

A sample “suspected of containing” a nucleic acid may contain or not contain the target nucleic acid molecule.

As used herein, the term “sample” is used in its broadest sense. For example, in some embodiments, it is meant to include a specimen or culture (*e.g.*, microbiological culture), whereas in other embodiments, it is meant to include both biological and environmental samples (*e.g.*, suspected of comprising a target sequence, gene or template). In some embodiments, a sample may include a specimen of synthetic origin. Samples may be unpurified or may be partially or completely purified or otherwise processed.

The present technology is not limited by the type of biological sample used or analyzed. The present technology is useful with a variety of biological samples including, but not limited to, tissue (*e.g.*, organ (*e.g.*, heart, liver, brain, lung, stomach, intestine, spleen, kidney, pancreas, and reproductive organs), glandular, skin, and muscle), cell (*e.g.*, blood cell (*e.g.*, lymphocyte or erythrocyte), muscle cell, tumor cell, and skin cell), gas, bodily fluid (*e.g.*, blood or portion thereof, serum, plasma, urine, semen, saliva, *etc.*), or solid (*e.g.*, stool) samples obtained from a human (*e.g.*, adult, infant, or embryo) or animal (*e.g.*, cattle, poultry, mouse, rat, dog, pig, cat, horse, and the like). In some embodiments, biological samples may be solid food and/or feed products and/or ingredients such as dairy items, vegetables, meat and meat by-products, and waste. Biological samples may be obtained from all of the various families of domestic animals, as well as feral or wild animals, including, but not limited to, such animals as ungulates, bear, fish, lagomorphs, rodents, pinnipeds, *etc.*

Biological samples also include biopsies and tissue sections (*e.g.*, biopsy or section of tumor, growth, rash, infection, or paraffin-embedded sections), medical or hospital samples (*e.g.*, including, but not limited to, blood samples, saliva, buccal swab, cerebrospinal fluid, pleural fluid, milk, colostrum, lymph, sputum, vomitus, bile, semen, oocytes, cervical cells,

amniotic fluid, urine, stool, hair, and sweat), laboratory samples (*e.g.*, subcellular fractions), and forensic samples (*e.g.*, blood or tissue (*e.g.*, spatter or residue), hair and skin cells containing nucleic acids), and archeological samples (*e.g.*, fossilized organisms, tissue, or cells).

Environmental samples include, but are not limited to, environmental material such as surface matter, soil, water (*e.g.*, freshwater or seawater), algae, lichens, geological samples, air containing materials containing nucleic acids, crystals, and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items.

Samples may be prepared by any desired or suitable method. In some embodiments, nucleic acids are analyzed directly from bodily fluids, stool, or other samples using the methods described in U.S. Pat. No. 9,000,146.

The above described examples are not, however, to be construed as limiting the sample (*e.g.*, suspected of comprising a target sequence, gene or template (*e.g.*, the presence or absence of which can be determined using the compositions and methods of the present technology)) types applicable to the present technology.

The terms “nucleic acid sequence” and “nucleic acid molecule” as used herein refer to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof. The terms encompass sequences that include analogs of DNA and RNA nucleotides, including those listed above, and also including, but not limited to, 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxyl-methyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudo-uracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methyl-cytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxy-amino-methyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, 2,6-diaminopurine, and pyrazolo[3,4-d]pyrimidines such as guanine analogue 6 amino 1H-pyrazolo[3,4d]pyrimidin 4(5H) one (ppG or PPG, also Super G) and the adenine analogue 4 amino 1H-pyrazolo[3,4d]pyrimidine (ppA or PPA). The xanthine analogue 1H-pyrazolo[5,4d]pyrimidin 4(5H)-6(7H)-dione (ppX) can also be used.

These base analogues, when present in an oligonucleotide, strengthen hybridization and improve mismatch discrimination. All tautomeric forms of naturally-occurring bases, modified bases and base analogues may be included in the oligonucleotide conjugates of the technology. Other modified bases useful in the present technology include 6-amino-3-prop-1-ynyl-5-hydropyrazolo[3,4-d]pyrimidine-4-one, PPPG; 6-amino-3-(3-hydroxyprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidine-4-one, HOPPPG; 6-amino-3-(3-aminoprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidine-4-one, NH₂PPPG; 4-amino-3-(prop-1-ynyl)pyrazolo[3,4-d]pyrimidine, PPPA; 4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, HOPPPA; 4-amino-3-(3-aminoprop-1-ynyl)pyrazolo[3,4-d]pyrimidine, NH₂ PPPA; 3-prop-1-ynylpyrazolo[3,4-d]pyrimidine-4,6-diamino, (NH₂)₂ PPPA; 2-(4,6-diaminopyrazolo[3,4-d]pyrimidin-3-yl)ethyn-1-ol, (NH₂)₂ PPPAOH; 3-(2-aminoethynyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine, (NH₂)₂ PPPANH₂; 5-prop-1-ynyl-1,3-dihydropyrimidine-2,4-dione, PU; 5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2,4-dione, HOPU; 6-amino-5-prop-1-ynyl-3-dihydropyrimidine-2-one, PC; 6-amino-5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2-one, HOPC; and 6-amino-5-(3-aminoprop-1-ynyl)-1,3-dihydropyrimidine-2-one, NH₂PC; 5-[4-amino-3-(3-methoxyprop-1-ynyl)pyrazol[3,4-d]pyrimidinyl]-2-(hydroxymethyl)oxolan-3-ol, CH₃ OPPPA; 6-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-(3-methoxyprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidin-4-one, CH₃ OPPPG; 4, (4,6-Diamino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-but-3-yn-1-ol, Super A; 6-Amino-3-(4-hydroxy-but-1-ynyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one; 5-(4-hydroxy-but-1-ynyl)-1H-pyrimidine-2,4-dione, Super T; 3-iodo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH₂)₂PPAI); 3-bromo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH₂)₂PPABr); 3-chloro-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH₂)₂PPACl); 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPAI); 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPABr); and 3-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPACl).

A nucleic acid sequence or molecule may be DNA or RNA, of either genomic or synthetic origin, that may be single or double stranded, and represent the sense or antisense strand. Thus, nucleic acid sequence may be dsDNA, ssDNA, mixed ssDNA, mixed dsDNA, dsDNA made into ssDNA (*e.g.*, through melting, denaturing, helicases, *etc.*), A-, B-, or Z-DNA, triple-stranded DNA, RNA, ssRNA, dsRNA, mixed ss and dsRNA, dsRNA made into ssRNA (*e.g.*, via melting, denaturing, helicases, *etc.*), messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), catalytic RNA, snRNA, microRNA, or protein nucleic acid (PNA).

The present technology is not limited by the type or source of nucleic acid (*e.g.*, sequence or molecule (*e.g.* target sequence and/or oligonucleotide)) utilized. For example, the nucleic acid sequence may be amplified or created sequence (*e.g.*, amplification or creation of nucleic acid sequence via synthesis (*e.g.*, polymerization (*e.g.*, primer extension (*e.g.*, RNA-DNA hybrid primer technology)) and reverse transcription (*e.g.*, of RNA into DNA)) and/or amplification (*e.g.*, polymerase chain reaction (PCR), rolling circle amplification (RCA), nucleic acid sequence based amplification (NASBA), transcription mediated amplification (TMA), ligase chain reaction (LCR), cycling probe technology, Q-beta replicase, strand displacement amplification (SDA), branched-DNA signal amplification (bDNA), hybrid capture, and helicase dependent amplification).

The terms “nucleotide” and “base” are used interchangeably when used in reference to a nucleic acid sequence, unless indicated otherwise herein. A “nucleobase” is a heterocyclic base such as adenine, guanine, cytosine, thymine, uracil, inosine, xanthine, hypoxanthine, or a heterocyclic derivative, analog, or tautomer thereof. A nucleobase can be naturally occurring or synthetic. Non-limiting examples of nucleobases are adenine, guanine, thymine, cytosine, uracil, xanthine, hypoxanthine, 8-azapurine, purines substituted at the 8 position with methyl or bromine, 9-oxo-N6-methyladenine, 2-aminoadenine, 7-deazaxanthine, 7-deazaguanine, 7-deaza-adenine, N4-ethanocytosine, 2,6-diaminopurine, N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, thiouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, inosine, 7,8-dimethylalloxazine, 6-dihydrothymine, 5,6-dihydrouracil, 4-methyl-indole, ethenoadenine and the non-naturally occurring nucleobases described in U.S. Pat. Nos. 5,432,272 and 6,150,510 and PCT applications WO 92/002258, WO 93/10820, WO 94/22892, and WO 94/24144, and Fasman (“Practical Handbook of Biochemistry and Molecular Biology”, pp. 385-394, 1989, CRC Press, Boca Raton, LO.

The term “oligonucleotide” as used herein is defined as a molecule comprising two or more nucleotides (*e.g.*, deoxyribonucleotides or ribonucleotides), preferably at least 5 nucleotides, more preferably at least about 10–15 nucleotides and more preferably at least about 15 to 30 nucleotides, or longer (*e.g.*, oligonucleotides are typically less than 200 residues long (*e.g.*, between 15 and 100 nucleotides), however, as used herein, the term is also intended to encompass longer polynucleotide chains). The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides are often referred to by their length. For example a 24 residue oligonucleotide is referred to as a “24-mer”. Oligonucleotides can form secondary and

tertiary structures by self-hybridizing or by hybridizing to other polynucleotides. Such structures can include, but are not limited to, duplexes, hairpins, cruciforms, bends, and triplexes. Oligonucleotides may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, PCR, or a combination thereof. In some embodiments, oligonucleotides that form invasive cleavage structures are generated in a reaction (*e.g.*, by extension of a primer in an enzymatic extension reaction).

Because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage, an end of an oligonucleotide is referred to as the “5' end” if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the “3' end” if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends. A first region along a nucleic acid strand is said to be upstream of another region if the 3' end of the first region is before the 5' end of the second region when moving along a strand of nucleic acid in a 5' to 3' direction.

As used herein, the terms “complementary” or “complementarity” are used in reference to polynucleotides (*e.g.*, a sequence of two or more nucleotides (*e.g.*, an oligonucleotide or a target nucleic acid)) related by the base-pairing rules. For example, the sequence “5'-A-G-T-3',” is complementary to the sequence “3'-T-C-A-5'.” Complementarity may be “partial,” in which only some of the nucleic acid bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acid bases. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods that depend upon the association of two or more nucleic acid strands. Either term may also be used in reference to individual nucleotides, especially within the context of polynucleotides. For example, a particular nucleotide within an oligonucleotide may be noted for its complementarity, or lack thereof, to a nucleotide within another nucleic acid sequence (*e.g.*, a target sequence), in contrast or comparison to the complementarity between the rest of the oligonucleotide and the nucleic acid sequence.

The complement of a nucleic acid sequence as used herein refers to an oligonucleotide which, when aligned with the nucleic acid sequence such that the 5' end of one sequence is paired with the 3' end of the other, is in “antiparallel association.” Nucleotide

analogs, as discussed above, may be included in the nucleic acids of the present technology and include. Complementarity need not be perfect; stable duplexes may contain mismatched base pairs or unmatched bases. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength and incidence of mismatched base pairs.

As used herein, the term “label” refers to any moiety (*e.g.*, chemical species) that can be detected or can lead to a detectable response. In some preferred embodiments, detection of a label provides quantifiable information. Labels can be any known detectable moiety, such as, for example, a radioactive label (*e.g.*, radionuclides), a ligand (*e.g.*, biotin or avidin), a chromophore (*e.g.*, a dye or particle that imparts a detectable color), a hapten (*e.g.*, digoxigenin), a mass label, latex beads, metal particles, a paramagnetic label, a luminescent compound (*e.g.*, bioluminescent, phosphorescent or chemiluminescent labels) or a fluorescent compound.

A label may be joined, directly or indirectly, to an oligonucleotide or other biological molecule. Direct labeling can occur through bonds or interactions that link the label to the oligonucleotide, including covalent bonds or non-covalent interactions such as hydrogen bonding, hydrophobic and ionic interactions, or through formation of chelates or coordination complexes. Indirect labeling can occur through use of a bridging moiety or “linker”, such as an antibody or additional oligonucleotide(s), which is/are either directly or indirectly labeled.

Labels can be used alone or in combination with moieties that can suppress (*e.g.*, quench), excite, or transfer (*e.g.*, shift) emission spectra (*e.g.*, fluorescence resonance energy transfer (FRET)) of a label (*e.g.*, a luminescent label).

A “polymerase” is an enzyme generally for joining 3'-OH 5'-triphosphate nucleotides, oligomers, and their analogs. Polymerases include, but are not limited to, template-dependent DNA-dependent DNA polymerases, DNA-dependent RNA polymerases, RNA-dependent DNA polymerases, and RNA-dependent RNA polymerases. Polymerases include but are not limited to T7 DNA polymerase, T3 DNA polymerase, T4 DNA polymerase, T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, DNA polymerase I, Klenow fragment, *Thermophilus aquaticus* DNA polymerase, Tth DNA polymerase, Vent DNA polymerase (New England Biolabs), Deep Vent DNA polymerase (New England Biolabs), Bst DNA Polymerase Large Fragment, Stoeffel Fragment, 9°N DNA Polymerase, Pfu DNA Polymerase, Tfl DNA Polymerase, RepliPhi Phi29 Polymerase, Tli DNA polymerase, eukaryotic DNA polymerase beta, telomerase, Terminator polymerase (New England

Biolabs), KOD HiFi DNA polymerase (Novagen), KOD1 DNA polymerase, Q-beta replicase, terminal transferase, AMV reverse transcriptase, M-MLV reverse transcriptase, Phi6 reverse transcriptase, HIV-1 reverse transcriptase, novel polymerases discovered by bioprospecting, and polymerases cited in US 2007/0048748, U.S. Pat. Nos. 6,329,178; 6,602,695; and 6,395,524. These polymerases include wild-type, mutant isoforms, and genetically engineered variants.

A “DNA polymerase” is a polymerase that produces DNA from deoxynucleotide monomers (dNTPs). “Eubacterial DNA polymerase” as used herein refers to the Pol A type DNA polymerases (repair polymerases) from Eubacteria, including but not limited to DNA Polymerase I from *E. coli*, Taq DNA polymerase from *Thermus aquaticus* and DNA Pol I enzymes from other members of genus *Thermus*, and other eubacterial species etc.

As used herein, the term “target” refers to a nucleic acid species or nucleic acid sequence or structure to be detected or characterized.

Accordingly, as used herein, “non-target”, *e.g.*, as it is used to describe a nucleic acid such as a DNA, refers to nucleic acid that may be present in a reaction, but that is not the subject of detection or characterization by the reaction. In some embodiments, non-target nucleic acid may refer to nucleic acid present in a sample that does not, *e.g.*, contain a target sequence, while in some embodiments, non-target may refer to exogenous nucleic acid, *i.e.*, nucleic acid that does not originate from a sample containing or suspected of containing a target nucleic acid, and that is added to a reaction, *e.g.*, to normalize the activity of an enzyme (*e.g.*, polymerase) to reduce variability in the performance of the enzyme in the reaction.

As used herein, the term “amplification reagents” refers to those reagents (deoxyribonucleoside triphosphates, buffer, *etc.*), needed for amplification except for primers, nucleic acid template, and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel.

As used herein, the term “control” when used in reference to nucleic acid detection or analysis refers to a nucleic acid having known features (*e.g.*, known sequence, known copy-number per cell), for use in comparison to an experimental target (*e.g.*, a nucleic acid of unknown concentration). A control may be an endogenous, preferably invariant gene against which a test or target nucleic acid in an assay can be normalized. Such normalizing controls for sample-to-sample variations that may occur in, for example, sample processing, assay efficiency, *etc.*, and allows accurate sample-to-sample data comparison. Genes that find use for normalizing nucleic acid detection assays on human samples include, *e.g.*, β -actin, ZDHHC1, and B3GALT6 (see, *e.g.*, U.S. Pat. Appln. Ser. Nos 14/966,617 and 62/364,082).

Controls may also be external. For example, in quantitative assays such as qPCR, QuARTS, etc., a “calibrator” or “calibration control” is a nucleic acid of known sequence, *e.g.*, having the same sequence as a portion of an experimental target nucleic acid, and a known concentration or series of concentrations (*e.g.*, a serially diluted control target for generation of calibration curve in quantitative PCR). Typically, calibration controls are analyzed using the same reagents and reaction conditions as are used on an experimental DNA. In certain embodiments, the measurement of the calibrators is done at the same time, *e.g.*, in the same thermal cycler, as the experimental assay. In preferred embodiments, multiple calibrators may be included in a single plasmid, such that the different calibrator sequences are easily provided in equimolar amounts. In particularly preferred embodiments, plasmid calibrators are digested, *e.g.*, with one or more restriction enzymes, to release calibrator portion from the plasmid vector. See, *e.g.*, WO 2015/066695.

As used herein “ZDHC1” refers to a gene encoding a protein characterized as a zinc finger, DHHC-type containing 1, located in human DNA on Chr 16 (16q22.1) and belonging to the DHHC palmitoyltransferase family.

As used herein, the term “process control” refers to an exogenous molecule, *e.g.*, an exogenous nucleic acid added to a sample prior to extraction of target DNA that can be measured post-extraction to assess the efficiency of the process and be able to determine success or failure modes. The nature of the process control nucleic acid used is usually dependent on the assay type and the material that is being measured. For example, if the assay being used is for detection and/or quantification of double stranded DNA or mutations in it, then double stranded DNA process controls are typically spiked into the samples pre-extraction. Similarly, for assays that monitor mRNA or microRNAs, the process controls used are typically either RNA transcripts or synthetic RNA. See, *e.g.*, U.S. Pat. Appl. Ser. No. 62/364,049, filed July 19, 2016, and which describes use of zebrafish DNA as a process control for human samples.

As used herein, the term “zebrafish DNA” is distinct from bulk “fish DNA”) *e.g.*, purified salmon DNA) and refers to DNA isolated from *Danio rerio*, or created *in vitro* (*e.g.*, enzymatically, synthetically) to have a sequence of nucleotides found in DNA from *Danio rerio*. In preferred embodiments, the zebrafish DNA is a methylated DNA added as a detectable control DNA, *e.g.*, a process control for verifying DNA recovery through sample processing steps. In particular, zebrafish DNA comprising at least a portion of the RASSF1 gene finds use as a process control, *e.g.*, for human samples, as described in U.S. Pat. Appl. Ser. No. 62/364,049.

As used herein the term “fish DNA” is distinct from zebrafish DNA and refers to bulk (*e.g.*, genomic) DNA isolated from fish, *e.g.*, as described in U.S. Patent No.9,212,392. Bulk purified fish DNA is commercially available, *e.g.*, provided in the form of cod and/or herring sperm DNA (Roche Applied Science, Mannheim, Germany) or salmon DNA (USB/Affymetrix).

As used herein, the terms “particle” and “beads” are used interchangeable, and the terms “magnetic particles” and “magnetic beads” are used interchangeably and refer to particles or beads that respond to a magnetic field. Typically, magnetic particles comprise materials that have no magnetic field but that form a magnetic dipole when exposed to a magnetic field, *e.g.*, materials capable of being magnetized in the presence of a magnetic field but that are not themselves magnetic in the absence of such a field. The term “magnetic” as used in this context includes materials that are paramagnetic or superparamagnetic materials. The term “magnetic”, as used herein, also encompasses temporarily magnetic materials, such as ferromagnetic or ferrimagnetic materials with low Curie temperatures, provided that such temporarily magnetic materials are paramagnetic in the temperature range at which silica magnetic particles containing such materials are used according to the present methods to isolate biological materials.

As used herein, the term “kit” refers to any delivery system for delivering materials. In the context of nucleic acid purification systems and reaction assays, such delivery systems include systems that allow for the storage, transport, or delivery of reagents and devices (*e.g.*, chaotropic salts, particles, buffers, denaturants, oligonucleotides, filters *etc.* in the appropriate containers) and/or supporting materials (*e.g.*, sample processing or sample storage vessels, written instructions for performing a procedure, *etc.*) from one location to another. For example, kits include one or more enclosures (*e.g.*, boxes) containing the relevant reaction reagents and/or supporting materials. As used herein, the term “fragmented kit” refers to a delivery system comprising two or more separate containers that each contains a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain an materials for sample collection and a buffer, while a second container contains capture oligonucleotides and denaturant. The term “fragmented kit” is intended to encompass kits containing Analyte specific reagents (ASR's) regulated under section 520(e) of the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the term “fragmented kit.” In contrast, a “combined kit” refers to a delivery

system containing all of the components of a reaction assay in a single container (*e.g.*, in a single box housing each of the desired components). The term “kit” includes both fragmented and combined kits.

The term “system” as used herein refers to a collection of articles for use for a particular purpose. In some embodiments, the articles comprise instructions for use, as information supplied on *e.g.*, an article, on paper, on recordable media (*e.g.*, diskette, CD, flash drive, *etc.*). In some embodiments, instructions direct a user to an online location, *e.g.*, a website for viewing, hearing, and/or downloading instructions. In some embodiments, instructions or other information are provided as an application (“app”) for a mobile device.

DETAILED DESCRIPTION OF THE INVENTION

Provided herein is technology relating to the amplification-based detection of nucleic acids and particularly, but not exclusively, to methods for enriching low-DNA, bisulfite-converted samples for analysis.

Biological samples of interest may have vastly different amounts of DNA in them, and even if rich in bulk DNA, may have very low amounts of DNAs of interest, *e.g.*, non-normal DNAs within a background of normal DNA, or human DNA in a background of microbial DNA (or vice versa). To compensate for a low concentration of target DNA, a large sample may sometimes be processed to collect sufficient DNA for a particular assay. However, when it is desirable to subject a sample with a low concentration of target DNA to a number of different assays in parallel, the necessary sample size may become prohibitively large. For example, circulating free DNA in plasma of a subject is typically very low, as it is continuously cleared from the bloodstream, mainly by the liver, and has a half-life of only 10 to 15 minutes. The typical levels of circulating DNA are thus very low, *e.g.*, for healthy individuals, a particular segment of DNA, *e.g.*, from a gene of interest, may be present at about 1,500 - 2000 copies/mL, while a segment of DNA associated with a tumor may be present at about 5000 copies/mL in a subject with a late stage cancer. Further, tumor-derived cfDNA in plasma is typically fragmented into short strands, *e.g.*, of 200 or fewer base pairs (see, *e.g.*, P. Jiang, et al., Proc. Natl Acad Sci. 112(11): E1317-E1325 (2015). Such small DNAs are especially hard to purify because they can be lost during typical purification steps, *e.g.*, through inefficiencies in precipitation and/or DNA binding purification steps.

Recovery of the DNA from such blood fraction samples may capture 75%, but often much less is recovered. Thus, depending on the sensitivity of the particular assay for these

targets, analysis of multiple DNA markers from plasma can require large amounts of plasma from a subject. Enrichment by targeted pre-amplification of specific target regions can increase the number of markers that can be analyzed using the same starting sample, *i.e.*, without the need to collect correspondingly larger samples (*e.g.*, plasma or blood) from the subject.

Provided herein are embodiments of technologies for extraction of DNA, *e.g.*, cell-free circulating DNA, from plasma samples. In preferred embodiments, the methods provided herein do not comprise organic extraction (*e.g.*, phenol-chloroform extraction), alcohol precipitation, or use of columns, making the methods readily scalable and automatable. In particularly preferred embodiments, essentially the entire isolation procedure – from plasma sample to bead-bound purified DNA ready for elution- is performed at room temperature.

Provided herein are embodiments of technologies for multiplexed pre-amplification particularly suited for analysis of target DNAs that are in low abundance and/or that are fragmented in the samples in which they are found, and that have been treated with bisulfite reagent, *e.g.*, as described in Leontiou, et al., PLoS ONE 10(8): e0135058. doi:10.1371/journal.pone.0135058 (2015). In certain preferred embodiments, the bisulfite treatment comprises use of ammonium hydrogen sulfite, with desulfonation preferably performed on support-bound DNA, as described in US Pat. No. US 9,315,853.

Embodiments of the technology

1. Isolation of circulating cell-free DNA from plasma

Provided herein is technology related to isolation of fragmented DNA from samples, *e.g.*, blood or plasma samples. In particular, provided herein is technology related to extraction of low-copy, small DNAs, *e.g.*, less than about 200 base pairs in length, from plasma samples, using mixable particles, *e.g.*, silica particles, to bind DNA. Methods are provided herein using two different lysis reagents, added at different times during the lysis treatment of the plasma sample, and using a combination of two different wash buffers in the processing of DNA bound to the particles. In preferred embodiments, the technology provided herein comprises addition of a bulk exogenous non-target DNA, *e.g.*, bulk fish DNA, to the DNA to be isolated for further analysis, preferably added to the plasma prior to or at the first particle-binding step.

2. Pre-amplification of target regions for PCR-flap assay analysis

Provided herein is technology related to providing an increased amount of DNA for analysis in a PCR-flap assay, e.g., a QuARTS assay as diagramed in Figure 1. In particular, embodiments of the methods and compositions disclosed herein provide for increasing an amount of a DNA target of interest, e.g., from a low-target sample, using a multiplexed pre-amplification step, followed by target-specific detection to further amplify and to detect the target locus of interest.

Re-amplifying DNA segments previously amplified in a targeted manner, e.g., amplification of an aliquot or dilution of the amplicon product of a target-specific PCR, is known to be prone to undesirable artifacts, e.g., high background of undesired DNA products. Thus, analysis of target nucleic acids using sequential rounds of specific PCR is typically conducted under special conditions, e.g., using different primers pairs in the sequential reactions. For example, in “nested PCR” the first round of amplification is conducted to produce a first amplicon, and the second round of amplification is conducted using a primer pair in which one or both of the primers anneal to sites inside the regions defined by the initial primer pair, i.e., the second primer pair is considered to be “nested” within the first primer pair. In this way, background amplification products from the first PCR that do not contain the correct inner sequence are not further amplified in the second reaction. Other strategies to reduce undesirable effects include using very low concentrations of primers in the first amplification.

Multiplex amplification of a plurality of different specific target sequences is typically conducted using relatively standard PCR reagent mixtures, e.g., for Amplitaq DNA polymerase, mixtures comprising 50 mM KCl, 1.5 to 2.5 mM MgCl₂, and Tris-HCl buffer at about pH 8.5 are used. As discussed above, if a second amplification is to be performed, the primers are typically present in limited amounts (Andersson, *supra*). For a subsequent assay, the amplified DNA is diluted or purified, and a small aliquot is then added to a detection assay, e.g., a PCR-flap assay, which uses different buffer and salt conditions than standard PCR (e.g., a buffer comprising MOPS, Tris-HCl pH 8.0, and 7.5 mM MgCl₂, and little or no added KCl or other monovalent salt, conditions typically considered unfavorable for PCR due to the low monovalent salt and the relatively high concentration of Mg⁺⁺ (see, e.g., “Guidelines for PCR Optimization with Taq DNA Polymerase” <https://www.neb.com/tools-and-resources/usage-guidelines/guidelines-for-pcr-optimization-with-taq-dna-polymerase>, which discloses 1.5 mM to 2.0 mM as the optimal Mg⁺⁺ range for Taq DNA polymerase,

with optimization to be conducted by supplementing the magnesium concentration in 0.5 increments up to 4 mM. See also “Multiplex PCR: Critical Parameters and Step-by-Step Protocol” O. Henegariu, et al., *BioTechniques* 23:504-511 (September 1997). A change in reaction conditions between a first amplification and a second amplification (or other detection assay) is often effected by either purifying the DNA from the first amplification reaction or by using sufficient dilution such that the amounts of reaction components carried into the follow-on reaction is negligible.

Embodiments of the present technology are directed to combining bisulfite modification, multiplex PCR amplification, and PCR-flap assay detection for the detection of low-copy number DNAs. During development of embodiments of the technology provided herein, it was discovered that use of a PCR-flap assay buffer with very low KCl and comprising elevated Mg^{++} (e.g., >6 mM, preferably > 7mM, more preferably 7.5mM), for both the multiplex pre-amplification in the absence of the flap assay reagents (e.g., in the absence of the hairpin oligonucleotide and FEN-1 endonuclease) and for the following PCR-flap assay produced substantially better signal. Further, it was unexpectedly determined that using the same primer pair to amplify a target region in both the pre-amplification and in the subsequent PCR-flap assay reaction produced better results than using a nested arrangement of primers. Use of the PCR-flap assay primers pairs in the initial amplification and in the PCR-flap assay has the advantage of producing signal from very small fragments of target DNA, such as would be expected in remote DNA samples. For example, amplicons of about 50 to 85 base pairs are produced and detected in examples hereinbelow).

In some embodiments, the one or both of the pre-amplification and the PCR-flap assay comprise exogenous, non-target DNA in the reaction mixture, as described, e.g., in U.S. Patent App. Ser. No.14/036,649, filed 9/25/2013. In certain preferred embodiments, the exogenous non-target DNA comprises fish DNA. While not limiting the invention to any particular mechanism of action, it has been observed that the presence of hairpin oligonucleotides (e.g., hairpin FRET cassettes as used, for example, in some embodiments of invasive cleavage detection assays) may have an inhibiting effect on DNA polymerase present in the same vessel, as assessed by sample and signal amplification. See, e.g., U.S. Patent Publication 2006/0147955 to Allawi. Allawi et al. observed that when PCR and invasive cleavage assay components were combined, the hairpin FRET oligonucleotides affected polymerase performance, and the use of purified exogenous non-target DNA, especially genomic DNA, improves the consistency of signal produced in such assays. Thus, in preferred embodiments, purified exogenous non-target DNA is added to samples before

and/or while contacting the samples with an enzyme such as a polymerase. The non-target DNA is typically added to the sample or reaction mixture, for example, at a concentration of approximately 2 to 20 ng per μL of reaction mixture, preferably approximately 6 to approximately 7 ng per μL of reaction mixture, when approximately 0.01 to 1.0 U/ μL of enzyme, *e.g.*, 0.05 U/ μL of enzyme (*e.g.*, a polymerase such as, *e.g.*, Taq polymerase) is used in the assay.

Embodiments of the multiplex pre-amplification as disclosed herein find use with PCR-flap assays such as the QuARTS assay. As diagrammed in Figure 1, the QuARTS technology combines a polymerase-based target DNA amplification process with an invasive cleavage-based signal amplification process. Fluorescence signal generated by the QuARTS reaction is monitored in a fashion similar to real-time PCR. During each amplification cycle, three sequential chemical reactions occur in each assay well, with the first and second reactions occurring on target DNA templates and the third occurring on a synthetic DNA target labeled with a fluorophore and quencher dyes, thus forming a fluorescence resonance energy transfer (FRET) donor and acceptor pair. The first reaction produces amplified target with a polymerase and oligonucleotide primers, and the second reaction uses a highly structure-specific 5'-flap endonuclease-1 (FEN-1) enzyme reaction to release a 5'-flap sequence from a target-specific oligonucleotide probe that binds to the product of the polymerase reaction, forming an overlap flap substrate. In the third reaction, the cleaved flap anneals to a specially designed oligonucleotide containing a fluorophore and quencher closely linked in a FRET pair such that the fluorescence is quenched (FRET cassette). The released probe flap hybridizes in a manner that forms an overlap flap substrate that allows the FEN-1 enzyme to cleave the 5'-flap containing the fluorophore, thus releasing it from proximity to the quencher molecule. The released fluorophore generates fluorescence signal to be detected. During the second and third reactions, the FEN-1 endonuclease can cut multiple probes per target, generating multiple cleaved 5'-flaps per target, and each cleaved 5' flap can participate in the cleavage of many FRET cassettes, giving rise to additional fluorescence signal amplification in the overall reaction.

In some configurations, each assay is designed to detect multiple genes, *e.g.*, 3 genes reporting to 3 distinct fluorescent dyes. See, *e.g.*, Zou, et al., (2012) "Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology", *Clinical Chemistry* **58**: 2.

These embodiments are further understood by the illustrative examples provided below.

EXPERIMENTAL EXAMPLES

EXAMPLE 1

DNA isolation from cells and plasma and bisulfite conversion

DNA isolation

For cell lines, genomic DNA was isolated from cell-conditioned media using the “Maxwell® RSC ccfDNA Plasma Kit (Promega Corp., Madison, WI). Following the kit protocol, 1 mL of cell-conditioned media (CCM) is used in place of plasma, and processed according to the kit procedure. The elution volume is 100 µL, of which 70 µL are used for bisulfite conversion.

An exemplary procedure for isolating DNA from a 4 mL sample of plasma would be conducted as follows:

- To a 4 mL sample of plasma, 300 µL of proteinase K (20mg/mL) is added and mixed.
- Add 3 µL of 1 µg/µL of Fish DNA to the plasma-proteinase K mixture.
- Add 2 mL of plasma lysis buffer to plasma.

Plasma lysis buffer is:

- 4.3M guanidine thiocyanate
- 10% IGEPAL CA-630 (Octylphenoxy poly(ethyleneoxy)ethanol, branched)
(5.3g of IGEPAL CA-630 combined with 45 mL of 4.8 M guanidine thiocyanate)

- Incubate mixtures at 55°C for 1 hour with shaking at 500 rpm.
- Add 3 mL of plasma lysis buffer and mix.
- Add 200 µL magnetic silica binding beads [16 µg of beads/µL] and mix again.
- Add 2 mL of 100% isopropanol and mix.
- Incubate at 30°C for 30 minutes with shaking at 500 rpm.
- Place tube(s) on magnet and let the beads collect. Aspirate and discard the supernatant.
- Add 750µL guanidine hydrochloride-ethyl alcohol (GuHCl-EtOH) wash solution to vessel containing the binding beads and mix.

GuHCl-EtOH wash solution is:

- 3M GuHCl

- 57% EtOH.

- Shake at 400 rpm for 1 minute.
- Transfer samples to a deep well plate or 2 mL microfuge tubes.
- Place tubes on magnet and let the beads collect for 10 minutes. Aspirate and discard the supernatant.
- Add 1000 μ L wash buffer (10 mM Tris HCl, 80% EtOH) to the beads, and incubate at 30°C for 3 minutes with shaking.
- Place tubes on magnet and let the beads collect. Aspirate and discard the supernatant.
- Add 500 μ L wash buffer to the beads and incubate at 30°C for 3 minutes with shaking.
- Place tubes on magnet and let the beads collect. Aspirate and discard the supernatant.
- Add 250 μ L wash buffer and incubate at 30°C for 3 minutes with shaking.
- Place tubes on magnet and let the beads collect. Aspirate and discard the remaining buffer.
- Add 250 μ L wash buffer and incubate at 30°C for 3 minutes with shaking.
- Place tubes on magnet and let the beads collect. Aspirate and discard the remaining buffer.
- Dry the beads at 70°C for 15 minutes, with shaking.
- Add 125 μ L elution buffer (10 mM Tris HCl, pH 8.0, 0.1 mM EDTA) to the beads and incubate at 65°C for 25 minutes with shaking.
- Place tubes on magnet and let the beads collect for 10 minutes.
- Aspirate and transfer the supernatant containing the DNA to a new vessel or tube.

Bisulfite conversion

I. Sulfonation of DNA using ammonium hydrogen sulfite

1. In each tube, combine 64 μ L DNA, 7 μ L 1 N NaOH, and 9 μ L of carrier solution containing 0.2 mg/mL BSA and 0.25 mg/mL of fish DNA.
2. Incubate at 42°C for 20 minutes.
3. Add 120 μ L of 45% ammonium hydrogen sulfite and incubate at 66° for 75 minutes.
4. Incubate at 4°C for 10 minutes.

II. Desulfonation using magnetic beads

Materials

Magnetic beads (Promega MagneSil Paramagnetic Particles, Promega catalogue number AS1050, 16 µg/µL).

Binding buffer: 6.5-7 M guanidine hydrochloride.

Post-conversion Wash buffer: 80% ethanol with 10 mM Tris HCl (pH 8.0).

Desulfonation buffer: 70% isopropyl alcohol, 0.1 N NaOH was selected for the desulfonation buffer.

Samples are mixed using any appropriate device or technology to mix or incubate samples at the temperatures and mixing speeds essentially as described below. For example, a Thermomixer (Eppendorf) can be used for the mixing or incubation of samples. An exemplary desulfonation is as follows:

1. Mix bead stock thoroughly by vortexing bottle for 1 minute.
2. Aliquot 50 µL of beads into a 2.0 mL tube (e.g., from USA Scientific).
3. Add 750 µL of binding buffer to the beads.
4. Add 150 µL of sulfonated DNA from step I.
5. Mix (e.g., 1000 RPM at 30°C for 30 minutes).
6. Place tube on the magnet stand and leave in place for 5 minutes. With the tubes on the stand, remove and discard the supernatant.
7. Add 1,000 µL of wash buffer. Mix (e.g., 1000 RPM at 30°C for 3 minutes).
8. Place tube on the magnet stand and leave in place for 5 minutes. With the tubes on the stand, remove and discard the supernatant.
9. Add 250 µL of wash buffer. Mix (e.g., 1000 RPM at 30°C for 3 minutes).
10. Place tube on magnetic rack; remove and discard supernatant after 1 minute.
11. Add 200 µL of desulfonation buffer. Mix (e.g., 1000 RPM at 30°C for 5 minutes).
12. Place tube on magnetic rack; remove and discard supernatant after 1 minute.
13. Add 250 µL of wash buffer. Mix (e.g., 1000 RPM at 30°C for 3 minutes).
14. Place tube on magnetic rack; remove and discard supernatant after 1 minute.
15. Add 250 µL of wash buffer to the tube. Mix (e.g., 1000 RPM at 30°C for 3 minutes).
16. Place tube on magnetic rack; remove and discard supernatant after 1 minute.
17. Incubate all tubes at 30°C with the lid open for 15 minutes.

18. Remove tube from magnetic rack and add 70 μ L of elution buffer directly to the beads.
19. Incubate the beads with elution-buffer (e.g., 1000 RPM at 40°C for 45 minutes).
20. Place tubes on magnetic rack for about one minute; remove and save the supernatant.

The converted DNA is then used in pre-amplification and/or flap endonuclease assays, as described below.

EXAMPLE 2

Multiplex pre-amplification - Cycles of Pre-Amplification

Using a nested approach, the effect of the number of PCR cycles was examined by conducting 5, 7 or 10 cycles using the outer primer pairs for each target sample. The PCR-flap assays using inner primers were used to further amplify and to analyze the pre-amplified products.

- Experimental conditions:
 1. Sample source: DNA extracted from HCT116 cell lines and bisulfite treated as described above;
 2. 50 μ L pre-amplification PCR reactions.
 3. Targets regions tested: NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β -actin (see Figure 5)
 4. Reaction conditions used for both pre-amplification PCR and the PCR-flap assay:
 - 7.5 mM $MgCl_2$,
 - 10 mM MOPS,
 - 0.3 mM Tris-HCl, pH 8.0,
 - 0.8 mM KCl,
 - 0.1 μ g/ μ l BSA,
 - 0.0001% Tween-20,
 - 0.0001% IGEPAL CA-630,
 - 250 μ M dNTP)
 - GoTaq polymerase at 0.025 U/ μ l (Promega Corp., Madison, WI)

Primer pairs for bisulfite-converted NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β -actin, as shown in Figures 5A-5F, at 500 nM each primer in both the pre-amplification and the PCR-flap assay.

10 μ L of prepared bisulfite-treated target DNA are used in each 50 μ L PCR reaction. Pre-amplification cycling was as shown below:

Pre-Amplification Reaction Cycles:		
Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	varying
	68°C / 30"	
	72°C / 30"	
Cooling	40°C / 30"	1

After PCR, 10 μ L of the amplification reaction was diluted to 100 μ L in 10 mM Tris, 0.1 mM EDTA, and 10 μ L of the diluted amplification product are used in a standard PCR-flap assay, as described below. Comparative assays used a QuARTS PCR-flap assay directly on the bisulfite-treated DNA, without pre-amplification.

An exemplary QuARTS reaction typically comprises approximately 400–600 nM (*e.g.*, 500 nM) of each primer and detection probe, approximately 100 nM of the invasive oligonucleotide, approximately 600–700 nM of each FAM (*e.g.*, as supplied commercially by Hologic), HEX (*e.g.*, as supplied commercially by BioSearch Technologies, IDT), and Quasar 670 (*e.g.*, as supplied commercially by BioSearch Technologies) FRET cassettes, 6.675 ng/ μ L FEN-1 endonuclease (*e.g.*, Cleavase® 2.0, Hologic, Inc.), 1 unit Taq DNA polymerase in a 30 μ L reaction volume (*e.g.*, GoTaq® DNA polymerase, Promega Corp., Madison, WI), 10 mM 3-(*n*-morpholino) propanesulfonic acid (MOPS), 7.5 mM MgCl₂, and 250 μ M of each dNTP.

Exemplary QuARTS cycling conditions are as shown below:

QuARTS Reaction Cycle:			Acquisition
Stage	Temp / Time	Number of Cycles	
Pre-incubation	95°C / 3'	1	none
Amplification 1	95°C / 20"	10	none
	63°C / 30"		none
	70°C / 30"		none
Amplification 2	95°C / 20"	35	none
	53°C / 1'		single
	70°C / 30"		none
Cooling	40°C / 30"	1	none

The data are shown in Figure 6, and show that 10 cycles of pre-amplification gave the most consistent determination of the percentage of methylation, as compared to the PCR-flap assay performed without pre-amplification.

EXAMPLE 3

Nested primers vs. non-nested primers; PCR buffer vs. PCR-Flap Assay Buffer

Assays were conducted to compare using a nested primer arrangement to the use of the same PCR flap assay primers in both the pre-amplification and the PCR-flap assay steps, and to compare the use of a typical PCR buffer vs. a PCR-flap assay buffer during the pre-amplification step. The PCR-flap assay buffer was used. The typical PCR buffer was 1.5 mM MgCl₂, 20 mM Tris-HCl, pH 8, 50 mM KCl, 250 µM each dNTP; and the PCR-flap assay buffer was 7.5 mM MgCl₂, 10 mM MOPS, 0.3 mM Tris-HCl, pH 8.0, 0.8 mM KCl, 0.1 µg/µL BSA, 0.0001% Tween-20, 0.0001% IGEPAL CA-630, 250 µM each dNTP. Primer concentrations of 20 nM, 100 nM and 500 nM each primer were also compared.

- Experimental conditions:
 1. Sample source: DNA extracted from HCT116 cell lines and bisulfite treated;
 2. 50 µL PCR reactions.
 3. Targets regions tested: NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β-actin
 4. GoTaq polymerase at 0.025 U/µL.
 5. PCR or PCR-flap assay buffer, as described above,

6. Primer pairs for bisulfite-converted NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β -actin, as shown in Figures 5A-5F, at 20 nM, 100 nM and 500 nM each primer.

Pre-amplification cycling was as shown below:

Pre-Amplification Reaction Cycle:		
Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	11
	68°C / 30"	
	72°C / 30"	
Cooling	40°C / 30"	1

10 μ L of prepared bisulfite-treated target DNA were used in each 50 μ L PCR reaction. After PCR, 10 μ L of the pre-amplification reaction was diluted to 100 μ L in 10 mM Tris, 0.1 mM EDTA, and 10 μ L of the diluted amplification product are used in a standard PCR-flap assay, as described in Example 2.

The data are shown in Figure 7. The top panel shows expected yields calculated from starting DNA amounts and the second panel shows amounts detected using the primer and buffer conditions indicated. These data show that the highest nM concentrations of primers gave the highest amplification efficiency. Surprisingly, the PCR-flap assay buffer having relatively high Mg^{++} and low KCl (7.5 mM 0.8 mM, respectively), when used in the PCR pre-amplification, gave better results than use of a traditional PCR buffer having lower Mg^{++} and much higher KCl concentration (1.5mM and 50 mM, respectively). Further, using the PCR-flap assay primers (the “inner” primers and shown in Figures 5A-5F) in the pre-amplification PCR worked as well or better than using sets outer and inner primer pairs in a nested PCR arrangement.

EXAMPLE 4

Testing Cycles of Pre-Amplification in Flap Assay Buffer

Assays were conducted to determine effect of increasing the number of pre-amplification PCR cycles on background in both no target control samples and on samples containing target DNA.

Experimental conditions:

1. Sample source:
 - i) No target control = 20 ng/μL fish DNA and/or 10 mM Tris, 0.1 mM EDTA;
 - ii) Bisulfite-converted DNA isolated from plasma from a normal patient
 - iii) Bisulfite-converted DNA isolated from plasma from a normal patient combined with DNA extracted from HCT116 cell lines and bisulfite treated
2. 50 μL PCR reactions,
3. Targets regions tested: NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β-actin,
4. Reaction conditions used for both pre-amplification and PCR-flap assay:

7.5 mM MgCl₂,
 10 mM MOPS,
 0.3 mM Tris-HCl, pH 8.0,
 0.8 mM KCl,
 0.1 μg/μL BSA,
 0.0001% Tween-20,
 0.0001% IGEPAL CA-630,
 250 μM dNTP)
 GoTaq polymerase at 0.025 U/μl,

Primer pairs for bisulfite-converted NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β-actin, as shown in Figures 5A-5F, at 500 nM each primer.

Pre-amplification cycling was as shown below:

Pre-Amplification Reaction Cycle:		
Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	5, 10, 20, or 25
	68°C / 30"	
	72°C / 30"	
Cooling	40°C / 30"	1

After PCR, 10 μL of the amplification reaction was diluted to 100 μL in 10 mM Tris, 0.1 mM EDTA, and 10 μL of the diluted amplification product are used in a standard PCR-flap assay, as described in Example 1.

The data are shown in Figures 8A-8C, and showed that no background was produced in the no-target control reactions, even at the highest cycle number. However, the samples pre-amplified for 20 or 25 cycles showed a noticeable decrease in signal in the PCR-flap assay.

EXAMPLE 5

Multiplex Targeted Pre-amplification of Large-Volume Bisulfite-Converted DNA

To pre-amplify most or all of the bisulfite treated DNA from an input sample, a large volume of the treated DNA may be used in a single, large-volume multiplex amplification reaction. For example, DNA is extracted from a cell lines (*e.g.*, DFCI032 cell line (adenocarcinoma); H1755 cell line (neuroendocrine), using, for example, the Maxwell Promega blood kit # AS1400, as described above. The DNA is bisulfite converted, *e.g.*, as described in Example 1.

A pre-amplification is conducted in a reaction mixture containing 7.5 mM MgCl₂, 10 mM MOPS, 0.3 mM Tris-HCl, pH 8.0, 0.8 mM KCl, 0.1 µg/µL BSA, 0.0001% Tween-20, 0.0001% IGEPAL CA-630, 250 µM dNTP, (*e.g.*, 12 primer pairs/24 primers, in equimolar amounts, or with individual primer concentrations adjusted to balance amplification efficiencies of the different target regions), 0.025 units/µL HotStart GoTaq concentration, and 20 to 50% by volume of bisulfite-treated target DNA (*e.g.*, 10 µL of target DNA into a 50 µL reaction mixture, or 50 µL of target DNA into a 125 µL reaction mixture). Thermal cycling times and temperatures are selected to be appropriate for the volume of the reaction and the amplification vessel. For example, the reactions may be cycled as follows

Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	10
	64°C / 30"	
	72°C / 30"	
Cooling	4°C / Hold	1

After thermal cycling, aliquots of the pre-amplification reaction (*e.g.*, 10 µL) are diluted to 500 µL in 10 mM Tris, 0.1 mM EDTA. Aliquots of the diluted pre-amplified DNA (*e.g.*, 10 µL) are used in a QuARTS PCR-flap assay, *e.g.*, as described in Example 2.

EXAMPLE 6

Multiplex Targeted Pre-amplification of Bisulfite-Converted DNA from Stool Samples

The multiplex pre-amplification methods described above were tested on DNA isolated from human stool samples.

Sample source:

- i) 4 DNA samples captured from stool samples (see, *e.g.*, U.S. Patent No. 9,000,146) and bisulfite-treated according to Example 1, above, the samples having the following pathologies:

500237	Adenoma (AA)
500621	Adenocarcinoma (ACA)
780116	Normal
780687	Normal

- ii) No target control = 20 ng/ μ L bulk fish DNA and/or 10 mM Tris, 0.1 mM EDTA;

- 2. 50 μ L PCR reactions,
- 3. Targets regions tested: NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β -actin,
- 4. Reaction conditions used for both pre-amplification and PCR-flap assay:
 - 7.5 mM MgCl₂,
 - 10 mM MOPS,
 - 0.3 mM Tris-HCl, pH 8.0,
 - 0.8 mM KCl,
 - 0.1 μ g/ μ L BSA,
 - 0.0001% Tween-20,
 - 0.0001% IGEPAL CA-630,
 - 250 μ M dNTP)
 - GoTaq polymerase at 0.025 U/ μ L,

Primer pairs for bisulfite-converted NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β -actin, as shown in Figures 5A-5F, at 500 nM each primer.

Pre-amplification cycling was as shown below:

Pre-Amplification Reaction Cycle:		
Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	10
	68°C / 30"	
	72°C / 30"	
Cooling	40°C / 30"	1

After PCR, 10 µL of the amplification reaction was diluted to 100 µL in 10 mM Tris, 0.1 mM EDTA, and 10 µL of the diluted amplification product are used in a standard PCR-flap assay, as described in Example 2.

The data are shown in Figure 9, and show that no background was produced in the no-target control reactions. For samples in which the target markers are not expected to be methylated (normal samples) no signal for methylated markers was detected, while the percent methylation detected in the samples from subjects having adenoma or adenocarcinoma were consistent with the results obtained using a standard non-multiplexed QuARTS PCR-flap assay, *i.e.*, without a separate pre-amplification step.

EXAMPLE 6

Multiplex Targeted Pre-amplification of Bisulfite-Converted DNA from Plasma Samples

The multiplex pre-amplification methods described above were tested on DNA isolated from human plasma samples and treated with bisulfite, as described in Example 1.

Experimental conditions:

1. Sample source:
 - Extracted and bisulfite-treated 75 plasma samples from patients with colorectal cancer or stomach cancer, or from normal patients – 2 mL each.
2. 50 µL PCR reactions,
3. Targets regions tested: NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β-actin,
4. Reaction conditions used for both pre-amplification and PCR-flap assay:
 - 7.5 mM MgCl₂,
 - 10 mM MOPS,

0.3 mM Tris-HCl, pH 8.0,
0.8 mM KCl,
0.1 µg/µL BSA,
0.0001% Tween-20,
0.0001% IGEPAL CA-630,
250 µM dNTP)
GoTaq polymerase at 0.025 U/µl,

Primer pairs for bisulfite-converted NDRG4, BMP3, SFMBT2, VAV3, ZDHHC1, and β-actin, as shown in Figures 5A-5F, at 500 nM each primer.

Pre-amplification cycling was as shown below:

Pre-Amplification Reaction Cycle:		
Stage	Temp / Time	#of Cycles
Pre-incubation	95°C / 5'	1
Amplification 1	95°C / 30"	10
	68°C / 30"	
	72°C / 30"	
Cooling	40°C / 30"	1

After PCR, 10 µL of the amplification reaction was diluted to 100 µL in 10 mM Tris, 0.1 mM EDTA, and 10 µL of the diluted amplification product are used in a standard PCR-flap assay, as described in Example 2.

The data are shown in Figures 10A-10I. Figures 10A-10C compare the results using the multiplex pre-amplification plus the PCR-flap assay to the results from the same samples in which no pre-amplification is performed. Figures 10D-10F show the percent methylation calculated for each sample using the multiplex pre-amplification plus the PCR-flap assay, and Figures 10G-10I shows the percent recovery of the input strands in the multiplex pre-amplification plus the PCR-flap assay, as compared to the results from the same samples using the PCR-flap assay with no pre-amplification step. Using 3 markers (VAV3, SFMBT2, ZDHHC1) for colorectal cancer, these data showed 92% sensitivity (23/25), at 100% specificity. Embodiments of the technology disclosed herein offer at least 100-fold or greater sensitivity for detecting DNA from blood, *e.g.*, 2.5 copies from 4 mL of plasma, compared to 250 copies using the QuARTS PCR flap assay without pre-amplification.

EXAMPLE 7

An Exemplary Protocol for Complete Blood-to-Result Analysis of Plasma DNA

An example of a complete process for isolating DNA from a blood sample for use, *e.g.*, in a detection assay, is provided in this example. Optional bisulfite conversion and detection methods are also described.

I. Blood processing

Whole blood is collected in anticoagulant EDTA or Streck Cell-Free DNA BCT tubes. An exemplary procedure is as follows:

1. Draw 10 mL whole blood into vacutainers tube (anticoagulant EDTA or Streck BCT), collecting the full volume to ensure correct blood to anticoagulant ratio.
2. After collection, gently mix the blood by inverting the tube 8 to 10 times to mix blood and anticoagulant and keep at room temperature until centrifugation, which should happen within 4 hours of the time of blood collection.
3. Centrifuge blood samples in a horizontal rotor (swing-out head) for 10 minutes at 1500 g (± 100 g) at room temperature. Do not use brake to stop centrifuge.
4. Carefully aspirate the supernatant (plasma) at room temperature and pool in a centrifuge tube. Make sure not to disrupt the cell layer or transfer any cells.
5. Carefully transfer 4mL aliquots of the supernatant into cryovial tubes.
6. Close the caps tightly and place on ice as soon as each aliquot is made. This process should be completed within 1 hour of centrifugation.
7. Ensure that the cryovials are adequately labeled with the relevant information, including details of additives present in the blood.
8. Specimens can be kept frozen at -20°C for a maximum of 48 hours before transferring to a -80°C freezer.

II. Preparation of a synthetic process control DNA

Complementary strands of methylated zebrafish DNA are synthesized having the sequences as shown below using standard DNA synthesis methods such as phosphoramidite addition, incorporating 5-methyl C bases at the positions indicated. The synthetic strands are annealed to create a double-stranded DNA fragment for use as a process control.

A. Annealing and Preparation of Concentrated Zebra Fish (ZF-RASS F1 180mer) Synthetic Process Control

Oligo Name	Oligo Sequence
Zebrafish <i>RASSF1</i> me synthetic Target Sense Strand	5-TCCAC/iMe-dC/GTGGTGCCCACTCTGGACAGGTGGAGCAGAGGGAAGGTGGT G/iMe-dC/GCATGGTGGG/iMe-dC/GAG/iMe-dC/G/iMe-dC/GTG/iMe-dC/GC CTGGAGGACCC/iMe-dC/GATTGGCTGA/iMe-dC/GTGTAACCAGGA/iMe-dC/GA GGACATGACTTTCAGCCCTGCAGCCAGACACAGCTGAGCTGGTGTGACCTGTGTGGA GAGTTCATCTGG-3
Zebrafish <i>RASSF1</i> me synthetic Target Anti-Sense Strand	5- CCAGATGAACTCTCCACACAGGTCACACCAGCTCAGCTGTGTCTGGCTGCAGGGCTG AAAGTCATGTCCT/iMe-dC/GTCCTGGTTTACA/iMe-dC/GTCAGCCAAT/iMe- dC/GGGGTCCTCCAGG/iMe-dC/GCA/iMe-dC/G/iMe-dC/GCT/iMe-dC/GC CCACCATG/iMe-dC/GCACCACCTCCCTCTGCTCCACCTGTCCAGAGTGG GCACCA/iMe-dC/GGTGGA-3

1. Reconstitute the lyophilized, single stranded oligonucleotides in 10 mM Tris, pH 8.0, 0.1 mM EDTA, at a concentration of 1 μ M.
2. Make 10X Annealing Buffer of 500mM NaCl, 200mM Tris-HCl pH 8.0, and 20mM MgCl₂.
3. Anneal the synthetic strands

In a total volume of 100 μ L, combine equimolar amounts of each of the single-stranded oligonucleotides in 1X annealing buffer, *e.g.*, as shown in the table below:

Component	Stock Conc.	Final Conc. (copies/ μ l in 1ml final volume)	Volume added (μ L)
Zebrafish <i>RASSF1</i> me synthetic Target Sense Strand	1 μ M	1.0E+10	16.6
Zebrafish <i>RASSF1</i> me synthetic Target Anti-Sense Strand	1 μ M	1.0E+10	16.6
Annealing Buffer	10X	NA	10.0
Water	NA	NA	56.8
		total vol.	100.0 μ L

4. Heat the annealing mixture to 98°C for 11-15 minutes.
5. Remove the reaction tube from the heat and spin down briefly to collect condensation to bottom of tube.
6. Incubate the reaction tube at room temp for 10 to 25 minutes.
7. Add 0.9 mL fish DNA diluent (20ng/mL bulk fish DNA in Te (10 mM Tris-HCl pH8.0, 0.1 mM EDTA)) to adjust to the concentration of zebrafish *RASSF1* DNA

fragment to 1.0×10^{10} copies/ μ L of annealed, double-stranded synthetic zebrafish *RASSF1* DNA in a carrier of genomic fish DNA.

8. Dilute the process control to a desired concentration with 10 mM Tris, pH 8.0, 0.1 mM EDTA, *e.g.*, as described in the table below, and store at either -20°C or -80°C

Initial Concentration	Target Addition	Te	Total Volume	Final Concentration
1.00E+10 copies/ μ L	10 μ L	990 μ L	1000 μ L	1.00E+08 copies/ μ L
1.00E+08 copies/ μ L	10 μ L	990 μ L	1000 μ L	1.00E+06 copies/ μ L

B. Preparation of 100x Stock Process Control (12,000 copies/ μ L Zebra Fish RASSF1 DNA in 200 ng/ μ L bulk Fish DNA)

1. Thaw reagents
2. Vortex and spin down thawed reagents
3. Add the following reagents into a 50 mL conical tube

Reagent	Initial Concentration	Final Concentration	Volume to add (mL)
Stock carrier fish DNA	10 μ g/ μ L	200 ng/ μ L	0.40
Zebra fish (ZF-RASS F1 180mer)	1.00E+06 copies/ μ L	1.20E+04 copies/ μ L	0.24
10 mM Tris, pH 8.0, 0.1 mM EDTA	NA	NA	19.36
		Total Volume	20.00

4. Aliquot into labeled 0.5 mL tubes and store @ -20°C

C. Preparation of 1x Stock of Process Control (120 copies/ μ L Zebra Fish RASSF1 DNA in 2 ng/ μ L Fish DNA)

1. Thaw reagents
2. Vortex and spin down thawed reagents
3. Add the following reagents into a 50 mL conical tube:

Reagent	1 mL	5 mL	10 mL
100x Zebra Fish Process Control	10 μ L	50 μ L	100 μ L
10 mM Tris, pH 8.0, 0.1 mM EDTA	990 μ L	4950 μ L	9900 μ L

4. Aliquot 0.3 mL into labeled 0.5 mL tubes and store @ -20°C

III. DNA extraction from plasma

1. Thaw plasma, prepare reagents, label tubes, and clean and setup biosafety cabinet for extraction
2. Add 300 μ L Proteinase K (20 mg/mL) to one 50 mL conical tube for each sample.
3. Add 2 - 4 mL of plasma sample to each 50 mL conical tube (do not vortex).
4. Swirl or pipet to mix and let sit at room temp for 5 min.
5. Add 4 - 6 mL of lysis buffer 1 (LB1) solution to bring the volume up to approximately 8 mL.

LB1 formulation:

- 0.1 mL of 120 copies/ μ L of zebrafish *RASSF1* DNA process control, as described above;
 - 0.9 -2.9 mL of 10 mM Tris, pH 8.0, 0.1 mM EDTA (*e.g.*, use 2.9 mL for 2 mL plasma samples)
 - 3 mL of 4.3 M guanidine thiocyanate with 10% IGEPAL (from a stock of 5.3g of IGEPAL CA-630 combined with 45 mL of 4.8 M guanidine thiocyanate)
6. Invert tubes 3 times.
 7. Place tubes on bench top shaker (room temperature) at 500 rpm for 30 minutes at room temperature.
 8. Add 200 μ L of silica binding beads [16 μ g of particles/ μ L] and mix by swirling.
 9. Add 7 mL of lysis buffer 2 (LB2) solution and mix by swirling.

LB2 formulation:

- 4 mL 4.3 M guanidine thiocyanate mixed with 10% IGEPAL
- 3 mL 100% Isopropanol

(Lysis buffer 2 may be added before, after, or concurrently with the silica binding beads)

10. Invert tubes 3 times.
11. Place tubes on bench top shaker at 500 rpm for 30 minutes at room temperature.
12. Place tubes on capture aspirator and run program with magnetic collection of the beads for 10 minutes, then aspiration. This will collect the beads for 10 minutes then remove all liquid from the tubes.
13. Add 0.9 mL of Wash Solution 1 (3 M guanidine hydrochloride or guanidine thiocyanate, 56.8% EtOH) to resuspend binding beads and mix by swirling.
14. Place tubes on bench top shaker at 400 rpm for 2 minute at room temperature.

(All subsequent steps can be done on the STARlet automated platform.)

15. Mix by repeated pipetting then transfer containing beads to 96 deep well plate.
16. Place plate on magnetic rack for 10 min.
17. Aspirate supernatant to waste.
18. Add 1 mL of Wash Solution 2 (80% Ethanol, 10 mM Tris pH 8.0).
19. Mix for 3 minutes.
20. Place tubes on magnetic rack for 10 min.
21. Aspirate supernatant to waste.
22. Add 0.5 mL of Wash Solution 2.
23. Mix for 3 minutes.
24. Place tubes on magnetic rack for 5 min.
25. Aspirate supernatant to waste.
26. Add 0.25 mL of Wash Solution 2.
27. Mix for 3 minutes.
28. Place tubes on magnetic rack for 5 min.
29. Aspirate supernatant to waste.
30. Add 0.25 mL of Wash Solution 2.
31. Mix for 3 minutes.
32. Place tubes on magnetic rack for 5 min.
33. Aspirate supernatant to waste.
34. Place plate on heat block at 70°C, 15 minutes, with shaking.
35. Add 125 µL of elution buffer (10 mM Tris-HCl, pH 8.0, 0.1 mM EDTA).
36. Incubate 65°C for 25 minutes with shaking.
37. Place plate on magnet and let the beads collect and cool for 8 minutes.
38. Transfer eluate to 96-well plate and store at -80°C. The recoverable/transferrable volume is about 100 µL.

IV. Pre-bisulfite DNA quantification

To measure DNA in samples using ACTB gene and to assess zebrafish process control recovery, the DNA may be measured prior to further treatment. Setup a QuARTS PCR-flap assay using 10 µL of the extracted DNA using the following protocol:

1. Prepare 10X Oligo Mix containing forward and reverse primers each at 2 μ M, the probe and FRET cassettes at 5 μ M and dNTP's at 250 μ M each. (See below for primer, probe and FRET sequences)

Oligo	Sequence (5'-3')	Concentration (μ M)
ZF RASSF1 UT forward primer	CGCATGGTGGGCGAG	2
ZF RASSF1 UT reverse primer	ACACGTCAGCCAATCGGG	2
ZF RASSF1 UT Probe (Arm 3)	CCACGGACG GCGCGTGCCTTT/3C6/	5
Arm 5 FAM FRET	/FAM/TCT/BHQ-1/AGCCGGTTTCCGGCTGAGACGTCCGTGG/3C6/	5
ACTB forward primer 3	CCATGAGGCTGGTGTAAAG	2
ACTB Reverse primer 3	CTACTGTGCACCTACTTAATACAC	2
ACTB probe with Arm 1	CGCCGAGGGCGGCCTTGGAG/3C6/	5
Arm 1 QUASAR670 FRET	/Q670/TCT/BHQ-2/AGCCGGTTTCCGGCTGAGACCTCGGCG/3C6/	5
dNTP mix		250

2. Prepare a master mix as follows:

Component	Volume per reaction (μ L)
Water	15.50
10X oligo Mix	3.00
20X QuARTS Enzyme Mix*	1.50
total volume	20.0

*20X enzyme mix contains 1 unit/ μ L GoTaq Hot start polymerase (Promega), 292 ng/ μ L Cleavase 2.0 flap endonuclease (Hologic).

3. Pipette 10 μ L of each sample into a well of a 96 well plate.
4. Add 20 μ L of master mix to each well of the plate.
5. Seal plate and centrifuge for 1 minutes at 3000 rpm.
6. Run plates with following reaction conditions on an ABI7500 or Light Cycler 480 real time thermal cycler

QuARTS Assay Reaction Cycle:				Signal Acquisition
Stage	Temp / Time	Ramp Rate (°C per second)	Number of Cycles	
Pre-incubation	95°C / 3 min	4.4	1	No
Amplification 1	95°C / 2 sec	4.4	5	No
	63°C / 30 sec	2.2		No
	70°C / 30 sec	4.4		No
Amplification 2	95°C / 20 sec	4.4	40	No
	53°C / 1 min	2.2		Yes
	70°C / 30 sec	4.4		No
Cooling	40°C / 30 sec	2.2	1	No

V. Bisulfite conversion and purification of DNA

1. Thaw all extracted DNA samples from the DNA extraction from plasma step and spin down DNA.
2. Reagent Preparation:

Component Abbreviation	Name	Formulation
BIS SLN	Bisulfite Conversion Solution	56.6% Ammonium Bisulfite
DES SLN	Desulfonation Solution	70% Isopropyl alcohol, 0.1 N NaOH
BND BDS	Binding Beads	Maxwell RNA Beads (16 mg/mL), (Promega Corp.)
BND SLN	Binding Solution	7 M Guanidine HCl
CNV WSH	Conversion Wash	10 mM Tris-HCl, 80% Ethanol
ELU BUF	Elution Buffer	10mM Tris, 0.1 mM EDTA, pH 8.0

3. Add 5 µL of 100 ng/µL BSA DNA Carrier Solution to each well in a deep well plate (DWP).
4. Add 80 µL of each sample into the DWP.
5. Add 5 µL of freshly prepared 1.6N NaOH to each well in the DWP(s).
6. Carefully mix by pipetting with pipette set to 30-40 µL to avoid bubbles.
7. Incubate at 42 °C for 20 minutes.
8. Add 120 µL of BIS SLN to each well.
9. Incubate at 66 °C for 75 minutes while mixing during the first 3 minutes.
10. Add 750 µL of BND SLN

11. Pre-mix of silica beads (BND BDS) and add of 50 μ L of Silica beads (BND BDS) to the wells of DWP.
12. Mix at 30°C on heater shaker at 1,200 rpm for 30 minutes.
13. Collect the beads on a plate magnet for 5 minutes followed by aspiration of solutions to waste.
14. Add 1 mL of wash buffer (CNV WSH) then move the plate to a heater shaker and mix at 1,200 rpm for 3 minutes.
15. Collect the beads on a plate magnet for 5 minutes followed by aspiration of solutions to waste.
16. Add 0.25 mL of wash buffer (CNV WSH) then move the plate to the heater shaker and mix at 1,200 rpm for 3 minutes.
17. Collect the beads on a plate magnet followed by aspiration of solutions to waste.
18. Add of 0.2 mL of desulfonation buffer (DES SLN) and mix at 1,200 rpm for 7 minutes at 30°C.
19. Collect the beads for 2 minutes on the magnet followed by aspiration of solutions to waste.
20. Add of 0.25 mL of wash buffer (CNV WSH) then move the plate to the heater shaker and mix at 1,200 rpm for 3 minutes.
21. Collect the beads for 2 minutes on the magnet followed by aspiration of solutions to waste.
22. Add of 0.25 mL of wash buffer (CNV WSH) then move the plate to the heater shaker and mix at 1,200 rpm for 3 minutes.
23. Collect the beads for 2 minutes on the magnet followed by aspiration of solutions to waste.
24. Allow the plate to dry by moving to heater shaker and incubating at 70°C for 15 minutes while mixing at 1,200 rpm.
25. Add 80 μ L of elution buffer (ELU BFR) across all samples in DWP.
26. Incubated at 65°C for 25 minutes while mixing at 1,200 rpm.
27. Manually Transfer eluate to 96well plate and store at -80°C
28. The recoverable/transferrable volume is about 65 μ L.

VI. QuARTS-X for methylated DNA detection and quantification

A. Multiplex PCR (mPCR) Setup:

1. Prepare a 10X primer mix containing forward and reverse primers for each methylated marker of interest to a final concentration of 750 nM each. Use 10 mM Tris-HCl, pH 8, 0.1 mM EDTA as diluent, as described in the examples above.
2. Prepare 10X multiplex PCR buffer containing 100 mM MOPS, pH 7.5, 75 mM MgCl₂, 0.08% Tween 20, 0.08% IGEPAL CA-630, 2.5 mM dNTPs.
3. Prepare multiplex PCR master mix as follows:

Component	Volume per reaction (μL)
Water	9.62
10X Primer Mix (0.75 μM each)	7.5
mPCR Buffer	7.5
Hot Start GoTaq (5 units/μl)	0.38
total volume	25.0

4. Thaw DNA and spin plate down.
5. Add 25 μL of master mix to a 96 well plate.
6. Transfer 50 μL of each sample to each well.
7. Seal plate with aluminum foil seal (do not use strip caps)
8. Place in heated-lid thermal cycler and proceed to cycle using the following profile, for about 5 to 20 cycles, preferably about 10 to 13 cycles:

Stage	Temp / Time	Number of Cycles
Pre-incubation	95°C / 5 min	1
Amplification 1	95°C / 30 sec	12
	64°C / 60 sec	
Cooling	4°C / hold	1

9. After completion of the thermal cycling, perform a 1:10 dilution of amplicon as follows:
 - a. Transfer 180 μL of 10 mM Tris-HCl, pH 8, 0.1 mM EDTA to each well of a deep well plate.
 - b. Add 20 μL of amplified sample to each pre-filled well.
 - c. Mix the diluted samples by repeated pipetting using fresh tips and a 200 μL pipettor (be careful not to generate aerosols).
 - d. Seal the diluted plate with a plastic seal.

- e. Centrifuge the diluted plate at 1000 rpm for 1 min.
- f. Seal any remaining multiplex PCR product that has not been diluted with a new aluminum foil seal. Place at -80 °C.

B. QuARTS Assay on multiplex-amplified DNA:

1. Thaw fish DNA diluent (20 ng/μL) and use to dilute plasmid calibrators (see, *e.g.*, U.S. Pat. Appln. Ser. No. 15/033,803) needed in the assay. Use the following table as a dilution guide:

Initial Plasmid Concentration, copies per μL	Final plasmid Concentration, copies per μL	μL of plasmid to add	μL of diluent to add	total volume, μL
1.00E+05	1.00E+04	5	45	50
1.00E+04	1.00E+03	5	45	50
1.00E+03	1.00E+02	5	45	50
1.00E+02	1.00E+01	5	45	50

2. Prepare 10X triplex QuARTS oligo mix using the following table for markers A, B, and C (*e.g.*, markers of interest, plus run control and internal controls such as β-actin or B3GALT6 (see, *e.g.*, U.S. Pat. Appln. Ser. No. 62/364,082).

Oligo	Sequence (5'-3')	Concentration (μM)
Marker A Forward primer	NA	2
Marker A Reverse primer	NA	2
Marker A probe-Arm 1	NA	5
Marker B Forward primer	NA	2
Marker B Reverse primer	NA	2
Marker B probe-Arm 5	NA	5
Marker C Forward primer	NA	2
Marker C Reverse primer	NA	2
Marker C probe-Arm 3	NA	5
A1 HEX FRET	/HEX/ TCT/BHQ- 1/AGCCGGTTTTCCGGCTGAGACCTCGGCG/3C6/	5
A5 FAM FRET	/FAM/ TCT/BHQ- 1/AGCCGGTTTTCCGGCTGAGACGTCCGTGG/3C6/	5
A3 QUASAR-670 FRET	/Q670/TCT/BHQ- 2/AGCCGGTTTTCCGGCTGAGACTCCGCGTC/3C6/	5
dNTP mix		250

For example, the following might be used to detect bisulfite-treated β-actin, B3GALT6, and zebrafish *RASSF1* markers:

Oligo Description	Sequence (5'-3')	Concentration (μM)
ZF RASSF1 BT Forward primer	TGCGTATGGTGGGCGAG	2
ZF RASSF1 BT Reverse primer	CCTAATTTACACGTCAACCAATCGAA	2
ZF RASSF1 BT probe-Arm 5	CCACGGACGGCGCGTGC GTTT/3C6/	5
B3GALT6 Forward primer	GGTTTATTTGGTTTTTTGAGTTTTCGG	2
B3GALT6 Reverse primer	TCCAACCTACTATATTTACGCGAA	2
B3GALT6 probe-Arm 1	CGCCGAGGGCGGATTTAGGG/3C6/	5
BTACT Forward primer	GTGTTTGT TTTTGTATTAGGTGTTTAAGA	2
BTACT Reverse primer	CTTTACACCAACCTCATAACCTTATC	2
BTACT probe-Arm 3	GACGCGGAGATAGTGTGTGG /3C6/	5
Arm 1 HEX FRET	/HEX/TCT/BHQ-1/AGCCGGTTTTCCGGCTGAGACCTCGGCG/3C6/	5
Arm 5 FAM FRET	/FAM/TCT/BHQ-1/AGCCGGTTTTCCGGCTGAGACGTCCGTGG/3C6/	5
Arm 3 QUASAR-670 FRET	/Q670/TCT/BHQ-2/AGCCGGTTTTCCGGCTGAGACTCCGCGTC/3C6/	5
dNTP mix		2500

3. Prepare a QuARTS flap assay master mix using the following table:

Component	Volume per reaction (μL)
Water	15.5
10X Triplex Oligo Mix	3.0
20X QuARTS Enzyme mix	1.5
total volume	20.0

*20X enzyme mix contains 1 unit/μL GoTaq Hot start polymerase (Promega), 292 ng/μL Cleavase 2.0 flap endonuclease (Hologic).

- Using a 96 well ABI plates, pipette 20 μL of QuARTS master mix into each well.
- Add 10 μL of appropriate calibrators or diluted mPCR samples.
- Seal plate with ABI clear plastic seals.
- Centrifuge the plate using 3000rpm for 1 minute.
- Place plate in ABI thermal cycler programmed to run the following thermal protocol then start the instrument

QuARTS Reaction Cycle:				Signal Acquisition
Stage	Temp / Time	Ramp Rate (°C per second)	Number of Cycles	
Pre-incubation	95°C / 3 min	4.4	1	none
Amplification 1	95°C / 2 sec	4.4	5	none
	63°C / 30 sec	2.2		none
	70°C / 30 sec	4.4		none
Amplification 2	95°C / 20 sec	4.4	40	none
	53°C / 1 min	2.2		Yes
	70°C / 30 sec	4.4		none
Cooling	40°C / 30 sec	2.2	1	none

EXAMPLE 8

Comparison of chaotropic salts in first wash solution

During development of the technology, the effects of using different chaotropic salts, *e.g.*, guanidine thiocyanate vs. guanidine hydrochloride in the first wash solution were compared.

DNA was extracted from plasma samples as described in Example 7, with either guanidine thiocyanate-ethyl alcohol or guanidine hydrochloride-ethyl alcohol used as a first wash solution (*i.e.*, 57% ethyl alcohol with either 3 M guanidine hydrochloride or 3 M guanidine thiocyanate). The samples were otherwise processed as described in Example 7 and a portion of the DNA was bisulfite-converted. The amount of resulting unconverted DNA was measured by detection of the process control and β -actin (ACTB) using a QuARTS PCR flap assay, as described above, and the bisulfite-converted DNA was measured by detection of the process control, B3GALT6, and β -actin (BTACT) using a multiplex pre-amplification and QuARTS PCR-flap assay, as described above. The results are shown in Figures 11A-11C (process control data not shown). These data show that both solutions produced acceptable DNA yields, with the guanidine thiocyanate-ethanol producing higher yields.

EXAMPLE 9

Comparison of ethyl alcohol with guanidine thiocyanate or guanidine hydrochloride to ethyl alcohol with buffer in a first wash step

During development of the technology, the effects of using a mixture of ethyl alcohol (ethanol) with a chaotropic salt solution, *e.g.*, guanidine thiocyanate (GTC) or guanidine

hydrochloride (GuHCl) in the first wash step of the plasma DNA extraction described in Example 7, part III *i.e.*, using 57% ethyl alcohol with 3 M guanidine hydrochloride (wash solution 1 in Example 7, part III) or 50% ethyl alcohol with 2.4 M guanidine thiocyanate, was compared to using 80% ethyl alcohol with 10 mM Tris HCl, pH 8.0 (wash solution 2 in Example 7, part III) in the first wash step. The 80% ethanol-Tris buffer solution was used in the subsequent wash steps, as described in Example 7.

Eight replicates were performed for each set of wash conditions. The samples were otherwise processed as described in Example 7 and the DNA was not treated with bisulfite. The amount of resulting DNA was measured by detection of β -actin (ACTB) using a QuARTS PCR flap assay, as described above. The results (mean of DNA strands detected) are shown in the table below. These data show that use of ethyl alcohol with either guanidine thiocyanate or guanidine hydrochloride in the first wash step, followed by additional washes with the ethanol-buffer wash, produced higher yields than the use of the ethanol-buffer wash for all wash steps.

Wash Condition	Mean	SD	CV
Ethanol-Tris buffer	1099	50.80	4.62
Ethanol-GuHCl	1434	76.49	5.33
Ethanol-GTC	1416	189.45	13.38

EXAMPLE 10

Test of addition of lysis reagent in one step or two step

During development of the technology, the effects of adding the lysis reagent at one or two steps in the isolation procedure were compared. Using aliquots of 2 mL or 4 mL from 6 different plasma samples, the first procedure comprised adding 7 mL of a lysis reagent of 4.3 M guanidine thiocyanate with 10% IGEPAL with proteinase K and a process control as described in Example 1, incubation of the plasma/protease/process control mixture at 55°C for 60 min, followed by addition of isopropanol. The second procedure comprised adding one aliquot of 3 mL of 4.3 M guanidine thiocyanate with 10% IGEPAL with the protease and process control, and a further aliquot of 4 mL added after the 55°C incubation, along with the addition of isopropanol. The samples were then further incubated at 30°C for 30 min., then processed as described in Example 1. A portion of the resulting DNA was bisulfite-converted as described.

The amount of resulting unconverted DNA was measured by detection of the process control and β -actin (ACTB) using a QuARTS assay, as described above, and the bisulfite-converted DNA was measured by detection of the process control, B3GALT6, and β -actin (BTACT) using a multiplex pre-amplification and QuARTS PCR-flap assay, as described above. The results are shown in Figures 12A-12C (process control data not shown). The average fold difference in yield for each tested marker and for the process control (PC) is shown below:

Average fold difference of 2 additions vs. 1 addition				
Unconverted		Bisulfite-converted		
PC	ACTB	PC	B3GALT	BTACT
1.07	1.12	1.04	1.12	1.20

These data show that addition of the lysis reagent in two steps, with the first in the absence of isopropanol and the second added in combination with isopropanol, produces higher yields of detectable DNA.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which the various embodiments described herein belongs. When definitions of terms appear to differ from the definitions provided in the present teachings, the definition provided in the present teachings shall control.

Various modifications and variations of the described compositions, methods, and uses of the technology will be apparent to those skilled in the art without departing from the scope and spirit of the technology as described. Although the technology has been described in connection with specific exemplary embodiments, it should be understood that the technology as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the technology that are obvious to those skilled in pharmacology, biochemistry, medical science, or related fields are intended to be within the scope of the following claims.

We claim:

1. A method of analyzing a sample for multiple target nucleic acids in a PCR flap assay, comprising:
 - a) providing a sample comprising DNA suspected of containing one or more of a plurality of different target regions,
 - b) treating the sample in an amplification reaction mixture comprising a PCR-flap assay buffer comprising between 6 to 10 mM Mg^{++} under conditions wherein the different target regions, if present in the sample, are amplified to form a pre-amplified mixture;
 - c) partitioning the pre-amplified mixture into a plurality of different PCR-flap assay reaction mixtures comprising the PCR-flap assay buffer; and
 - d) conducting a plurality of PCR-flap assays with the PCR-flap assay reaction mixtures, wherein the different target regions, if present in the sample at step a), are amplified and detected in the PCR-flap assay reaction mixtures.
2. The method of claim 1, wherein the DNA is from a human subject.
3. The method of claim 1 or claim 2, wherein the sample is prepared from a body fluid.
4. The method of claim 3, wherein the body fluid comprises plasma.
5. The method of any one of claims 1-4, wherein the sample is prepared from cell-free DNA isolated from plasma.
6. The method of any one of claims 1-5, wherein the DNA comprises bisulfite treated DNA.

7. The method of any one of claims 1-6 , wherein the amplification reaction mixture comprises at least 2 different primer pairs for amplifying at least 2 different target regions, and wherein each PCR-flap assay reaction mixture comprises an additional amount of a primer pair selected from the at least 2 different primer pairs.
8. The method of any one of claims 1-7, wherein the amplification reaction mixture comprises at least 3 different primer pairs for amplifying at least 3 different target regions, if present in the sample.
9. The method of any one of claims 1-8, wherein the amplification reaction mixture comprises at least 4 different primer pairs for amplifying at least 4 different target regions, if present in the sample.
10. The method any one of claims 1-9, wherein the pre-amplified mixture is diluted with a diluent prior to partitioning.
11. The method of any one of claims 1-10, wherein the amplification reaction mixture and/or the plurality of different PCR-flap assay reaction mixtures comprise bulk fish DNA.
12. The method of any one of claims 1-11, wherein the PCR-flap assay reaction mixtures comprise a FEN-1 endonuclease.
13. The method of any one of claims 1-12, wherein the amplification reaction mixture of step b) is exposed to thermal cycling conditions limited to fewer than 20 thermal cycles.
14. The method of any one of claims 1-13, wherein each PCR-flap assay reaction mixture further comprises:
 - i) a flap oligonucleotide, and
 - ii) a hairpin oligonucleotide comprising a region that is complimentary to a portion of the flap oligonucleotide.

15. The method of claim 14, wherein the hairpin oligonucleotide comprises a fluorophore moiety.
16. The method of any one of claims 1-15, wherein the plurality of different target regions comprises a reference target region.
17. The method of claim 16, wherein the reference target region comprises a region of *β -actin* or *ZDHHC1*.
18. The method of any one of claims 1-17, wherein the sample comprises a DNA process control.
19. The method of claim 18, wherein the DNA process control comprises a zebrafish *RASSF1* sequence.
20. The method of any one of claims 1-19, wherein the PCR-flap assay buffer comprises 3-(n-morpholino) propanesulfonic acid (MOPS) buffer.


FIG. 1

FIG. 2




FIG. 3





FIG. 4

FIG. 5C

BMP3 Target DNA SEQ ID NO: 90

5' CGGGCTCCGTGCGCCCTCGCCCACTGGTTGGAGTTCAACCCCTCGGCTCCGCCCGGCTCCTTGCG
CCTTCGGAGTGTCGCCAGCGACGGAGCCGCGCGGTACCTAGCCATGGCTGGGCGA 3'

Bisulfite-converted target DNA with primer sites:

1. SEQ ID NO: 91 3.

5' CGGGTTTCGTGCGTTTTCGTTTAGTTGGTTTGGA GTTTAAATTTTCGGTTTCGTCGTCGGTTTTCGCG 3'

TTTTTCGGAGTGTTTCGTAGCGA CGTCGGAGTCGACGCGTCG CGCGGGTATTTAGTTATGGTTGGGGGA 3'

4.

PCR-Flap assay design:

Arm1 - CGGTTTTCGCG/3C6/ SEQ ID NO: 92

SEQ ID NO: 27 | | | | | | | | | |

5' GTTTAAATTTTCGGTTTCGTCGTCGGTTTTCGCGTTTTCGGAGTTCGTCGCG 3'

| | | | | | | | | | | | | | | |

GTTTAAATTTTCGGTTTCGTCGTC>> <<AGCCTCACAAAGCATCGC

SEQ ID NO: 28 SEQ ID NO: 29 SEQ ID NO: 25

1. BMP3 Outer Forward Primer: 5' GGTTTCGTGCGTTTTCGTTTAGT 3'

2. BMP3 Outer Reverse Primer: 5' CCAACCATAAATAACCCGCG 3' SEQ ID NO: 26

3. BMP3 PCR/Flap assay Forward Primer: 5' GTTTAAATTTTCGGTTTCGTCGTC 3'

4. BMP3 PCR/Flap assay Reverse Primer: 5' CGCTACGAAACACTCCGA3' SEQ ID NO: 29

5. BMP3 Flap oligonucleotide: 5' CGCCGAGGCGGTTTTCGCG/3C6/3' SEQ ID NO: 30

FIG. 5D

NDRG4 Target DNA SEQ ID NO: 93

5' GACCGGGTGTCCCCCAGGCTCCGGTCGGGTCCCCCGTCCGCCCTCCGCCGCCACCGGGCACCCC
CAGCCGCCAGAAAGCGGAAGCCACGCGCGAGGGACCGCGGTC 3'

Bisulfite-converted target DNA with primer sites:

1. SEQ ID NO: 94 3.

5' GATCGG[GGTGTTTTTAGGTTTCGCGTC][CGGTTTTCGTTCGTTTTTTCGTTTCGTTATCGGGTATTT

[TAGTCGCGTAGAAGCGGAA][GTTACGCGCGAGGATCGCGGTT 3'

4. 2.

PCR-Flap assay design:

Arm5-GTTCGTTATCG/3C6/ SEQ ID NO: 95

SEQ ID NO: 37 | | | | | | | |

5' CGGTTTTTCGTTTCGTTTTTTCGTTTCGTTTATCGGGTATTTTAGTCGCGTAGAAGCGG 3'

| | | | | | | | | | | | | | : : : : : : : : : : : : : : SEQ ID NO: 35

CGGTTTTTCGTTTCGTTTTCG>> <<ATCAGCGCATCTCCGCC SEQ ID NO: 39

1. NDRG4 Outer Forward Primer: 5' GGTGTTTTTTAGGTTTCGCGTC 3'

2. NDRG4 Outer Reverse Primer: 5' GATCCCTCGCGGTAAC 3' SEQ ID NO: 36

3. NDRG4 PCR/Flap assay Forward Primer: 5' CGGTTTTCGTTTCGTTTTCG 3' SEQ ID NO: 38

4. NDRG4 PCR/Flap assay Reverse Primer: 5' CCGCCTTCTACGCGACTA 3' SEQ ID NO: 39

5. NDRG4 Flap oligonucleotide: 5' CCACGGACGGTTCGTTTATCG/3C6/ 3' SEQ ID NO: 40

β -actin	Target DNA	SEQ ID NO: 96
5'	CTCTGCAGGTTCTATTGCTTTTCCAGATGAGCTCTTTTCTGGTGTCTCTGACTAGTGCTAA	
	GACAGTGTTGTGGGTAGGTACTAACACTGGCTCGTGTACAAGCCATGAGGCTGGTGTAAGCGCCTTGGAG	
	TGTGTATTAAGTAGGTG 3'	

1. SEQ ID NO: 97

5' TTTTGTAGGTTTATTGTTTTTTTAGATGAGTTT TTTTTTTGGTGTTTGT TTTTGTAGGTGTTAA

3.

GATAGTGTTGTGGGTAGGTATTAATATTGGTTTGTGT GATAAGGTTATGAGGTTGGTG TAAAGTGGTTTGGAG

4.

TGTTGATTAAAGTAGGTG 3'

2.

Arm3-ATAGTGTGTGG/3C6/ SEQ ID NO: 98

|||||

5' TTTGTTTTTTGATTAGGTGTTAAGATAGTGTGTGGGTAGGTATTAATATTGTTTGTGTGATAAGGTTATGAGTTGGT 3'

|||||

TTTTGTTTTTTGATTAGGTGTTAAGA>>

SEQ ID NO: 48

1. β -actin Outer Forward Primer: 5' TTGTAGGTTTTTATTGTTTTTTTTTTAGATGAGTTT 3' SEQ ID NO: 45

2. β -actin Outer Reverse Primer: 5' CTACTTAATACACACTCCAAAACCACT 3' SEQ ID NO: 46

3. β -actin PCR/Flap assay Forward Primer: 5' TTTGTTTTTTTGTATTAGGTGTTTAAGA 3'

4. β -actin PCR/Flap assay Reverse Primer: 5' CACCAACCTCATAACCTTATC3' SEQ ID NO: 49

5. β -actin Flap oligonucleotide: 5' GACGCGGAGATAGTGTGTGG/3C6/ 3' SEQ ID NO: 79

ZDHHC1	Target DNA	SEQ ID NO: 99
5'	GGCAGCGCCGCTCTGGCCGCCCGGGGCCGACGCCACGCTGGCCGGCAGGCGCGTGC	5'
3'	GCCGTTTCGTAGCCCCGAGCAGCGGCGAGCCAGGGCGCCGGCGGCGGAGGCTGGTCTGGCTTAGCTGG	3'

1. SEQ ID NO: 100

GGGTAGCGTCGTTTGGTCGTTCCGCGGGCTCGGCGGTAGGCCTGCGGTC

3.

GGGTAGCGTCGTTTGGTCGTTCCGCGGGCTCGGCGGTAGGCCTGCGGTC

2.

CGTTTCGTGAGTTCGAGTAGCGGGCAGTTAGGCGGTGGTTGGTTAGTTGG

4.

GCACGCAAGCAG-Arm3 SEQ ID NO: 101

SEQ ID NO: 57
GTCCGGGTCGATAGTTACGTTGGCGGGTAGCGGTCGTCGTTTCGTGAGTTCGAGT 3'
|||||
GTCCGGGTCGATAGTTACG>
SEQ ID NO: 58
<<GCAAAAGCACTCAAGCTCA
SEQ ID NO: 59

- | | | | | |
|----|--------|--------------------------------|-----------------------------------|---------------|
| 1. | ZDHHCl | Outer Forward Primer: | 5' AGCGTCGTTTGGTCGTTTC 3' | SEQ ID NO: 55 |
| 2. | ZDHHCl | Outer Reverse Primer: | 5' GACGCCCTAAACTCGCC 3' | SEQ ID NO: 56 |
| 3. | ZDHHCl | PCR/Flap assay Forward Primer: | 5' GTCGGGGTCGATAGTTTACG 3' | SEQ ID NO: 58 |
| 4. | ZDHHCl | PCR/Flap assay Reverse Primer: | 5' ACTCGAACTCACGAAAACG 3' | SEQ ID NO: 59 |
| 5. | ZDHHCl | Flap oligonucleotide: | 5' GACGGCGGAGGACGAACGCACG/3C6/ 3' | SEQ ID NO: 60 |

FIG. 6

SampleID	Cycles	NDRG4 strands	BMP3 strands	BTACT strands	VAV3 strands	S897 strands	ZDHHCl strands	% Methylation (relative to ZDDHC1)				
								%NDRG4	%BMP3	%VAV3	%S897	%ZDHHCl
1-3	5	1,409	595	1,462	1,234	1,014	1,805	78%	33%	68%	56%	100%
4-6	7	10,033	4,490	9,369	6,672	5,938	15,364	65%	29%	43%	39%	100%
7-9	10	47,177	19,750	38,780	42,786	36,079	124,873	38%	16%	34%	29%	100%

FIG. 7

Flap assay with no pre-
Amplification (4 replicate QuARTS)

SampleID	10X Rxn Bfr in Pre-PCR	Primer Arrangement	[Primer Conc (ea)]	NDRG4 strands	BMP3 strands	BTACT strands	VAV3 strands	S897 strands	ZDHHC1 strands	% Methylation (relative to ZDDHC1)			
										%NDRG4	%BMP3	%VAV3	%S897
Estimated strands without dilution or preamplification			20 nM	954	426	872	1441	659	2590	37%	16%	25%	25%
Estimated strands diluted 1:10, without preamplification			100 nM	12	6	16	23	8	45	27%	13%	17%	17%
Theoretical amplified strands				24,536	12,069	33,753	46,344	15,698	91,722				

11 cycle pre-PCR/ 1:10 dilution/ (2 replicate PCR-flap assays)

SampleID	10X Rxn Bfr in Pre-PCR	Primer Arrangement	[Primer Conc (ea)]	NDRG4 strands	BMP3 strands	BTACT strands	VAV3 strands	S897 strands	ZDHHC1 strands	%NDRG4	%BMP3	%VAV3	%S897	%ZDHHC1
1	PCR	Nested	20 nM	20	14	29	52	31	39	50%	34%	133%	78%	100%
2			100 nM	39	42	29	190	80	116	33%	36%	163%	69%	100%
3			500 nM	190	673	55	1,387	1,847	455	42%	148%	305%	406%	100%
4	PCR	Non-nested	20 nM	30	43	78	56	33	58	52%	75%	97%	58%	100%
5			100 nM	65	44	64	455	66	164	40%	27%	278%	40%	100%
6			500 nM	113	115	103	7,852	163	876	13%	13%	896%	19%	100%
7	Flap assay	Nested	20 nM	4,304	2,355	3,265	18,474	9,826	11,085	39%	21%	167%	89%	100%
8			100 nM	26,950	8,016	22,159	51,204	32,635	55,438	49%	14%	92%	59%	100%
9			500 nM	46,338	14,350	34,855	71,679	85,947	152,463	30%	9%	47%	56%	100%
10	Flap assay	Non-nested	20 nM	17,084	4,791	23	26,294	9,081	27,148	63%	18%	97%	33%	100%
11			100 nM	111,863	41,706	2,369	116,338	58,688	236,314	47%	18%	49%	25%	100%
12			500 nM	22,582	78,335	16,796	191,221	52,142	420,780	5%	19%	45%	12%	100%
Control 1	Flap assay	Nested	500 nM	0	0	0	0	0	0	N/A	N/A	N/A	N/A	N/A
Control 2	PCR	Non-nested	500 nM	0	0	0	0	0	0	N/A	N/A	N/A	N/A	N/A
Control 3	Flap assay	Nested	500 nM	0	0	0	0	0	0	N/A	N/A	N/A	N/A	N/A
Control 4	PCR	Non-nested	500 nM	0	0	0	0	0	0	N/A	N/A	N/A	N/A	N/A

FIG. 8A

SampleID	Sample Type	Strands per Reaction					
		NDRG4	BMP3	BTACT	VAV3	S897	ZDHC1
Normal Plasma	No Pre-Amp	0	0	681	0	0	1
Theoretical strands/rxn after multiplex Pre-Amp	5 cycles	0	0	218	0	0	0
	10cycles	0	0	13,951	0	0	21
	20cycles	0	25	14,286,060	0	0	21,711
	25cycles	0	801	457,153,922	0	0	694,751
Normal Plasma +21ul CCM	No Pre-Amp	262	133	1,027	251	159	279
Theoretical strands/rxn after multiplex Pre-Amp	5 cycles	168	85	657	161	102	178
	10cycles	5,371	2,727	21,035	5,150	3,258	5,706
	20cycles	5,499,930	2,792,066	21,539,883	5,273,387	3,336,078	5,843,227
	25cycles	175,997,755	89,346,125	689,276,245	168,748,376	106,754,506	186,983,255

FIG. 8B

SampleID	Sample Type	Cycles	Strands per Reaction					
			NDRG4	BMP3	BTACT	VAV3	S897	ZDHC1
1-2	Normal Plasma +21ul CCM	5	189	191	733	163	91	257
3-4	Normal Plasma	5	0	0	345	0	0	2
NTC-f5	Fish DNA Diluent	5	0	1	0	0	0	0
NTC-t5	Tris EDTA buffer	5	0	0	0	0	0	0
5-6	Normal Plasma +21ul CCM	10	6,180	5,091	19,877	6,285	2,752	9,422
7-8	Normal Plasma	10	0	3	8,263	0	0	8
NTC-f10	Fish DNA Diluent	10	0	0	0	0	0	0
NTC-t10	Tris EDTA buffer	10	0	0	0	0	0	0
9-10	Normal Plasma +21ul CCM	20	3,668,073	Out of Range	1,690,537	1,227,373	436,520	Out of Range
11-12	Normal Plasma	20	0	2	1,079,721	0	1	4,273
NTC-f20	Fish DNA Diluent	20	0	0	0	2	0	0
NTC-t20	Tris EDTA buffer	20	0	0	0	0	0	0
13-14	Normal Plasma +21ul CCM	25	Out of Range	6,029,291	1,895,229	21,897,908	12,192,303	20,788,101
15-16	Normal Plasma	25	12	22	1,645,426	0	32	260,831
NTC-f25	Fish DNA Diluent	25	0	0	0	0	0	0
NTC-t25	Tris EDTA buffer	25	0	0	0	1	0	0
Normal Plasma	Direct QuARTs (N. Plasma)	N/A	0	0	681	0	0	1
NP+21ul CCM	Direct QuARTs (N. Plasma+21ulCCM)	N/A	262	133	1,027	251	159	279
NTC, fdNA	QuARTs CTRL (fish DNA dil)	N/A	0	0	0	0	0	0
NTC, Te	QuARTs CTRL (Tris EDTA buffer)	N/A	0	0	0	0	0	0

FIG. 8C

		% Methylation (based on ZDHHHC1)						
SampleID	Sample Type	Cycles	NDRG4 strands	BMP3 strands	BTACT strands	VAV3 strands	S897 strands	ZDHHHC1 strands
1-2	N. Plasma + 21ul CCM	5	73%	75%		64%	36%	100%
5-6	N. Plasma + 21ul CCM	10	66%	54%		67%	29%	100%
9-10	N. Plasma + 21ul CCM	20	ND	ND		ND	ND	ND
13-14	N. Plasma + 21ul CCM	25	ND	29%		105%	59%	100%
NP+21ul CCM	Direct QuARTs (N.Plasma+21ul(CCM)	N/A	94%	48%		90%	57%	100%

		% Recovery						
SampleID	Sample Type	Cycles	NDRG4 strands	BMP3 strands	BTACT strands	VAV3 strands	S897 strands	ZDHHHC1 strands
1-2	N. Plasma + 21ul CCM	5	112%	225%	112%	101%	90%	144%
3-4	Normal Plasma	5			158%			474%
NTC-f5	Fish DNA Diluent	5						
NTC-f5	Tris EDTA buffer	5						
5-6	N. Plasma + 21ul CCM	10	115%	187%	94%	122%	84%	165%
7-8	Normal Plasma	10			59%			37%
NTC-f10	Fish DNA Diluent	10						
NTC-f10	Tris EDTA buffer	10						
9-10	N. Plasma + 21ul CCM	20	67%	ND	8%	23%	13%	ND
11-12	Normal Plasma	20		7%	8%			20%
NTC-f20	Fish DNA Diluent	20						
NTC-f20	Tris EDTA buffer	20						
13-14	N. Plasma + 21ul CCM	25	ND	7%	0%	13%	11%	11%
15-16	Normal Plasma	25	#DIV/0!	3%	0%	#DIV/0!	#DIV/0!	38%
NTC-f25	Fish DNA Diluent	25						
NTC-f25	Tris EDTA buffer	25						
Normal Plasma	Direct QuARTs (N.Plasma)	N/A						
NP+21ul CCM	Direct QuARTs (N.Plasma+21ul(CCM)	N/A						
NTC, fDNA	QuARTs CTRL (fDNA dil)	N/A						
NTC, Te	QuARTs CTRL (Tris EDTA buffer)	N/A						

FIG. 9

SampleID	Pathology	Measured QuARTS							% Methylation			
		NDRG4	BMP3	BTACT	VAV3	SFMB2	ZDHHC1		% NDRG4	% BMP3	% VAV3	% SFMB2
500237	AA	73	53	7,723	1,239	159	3,217		2.3%	1.7%	38.5%	4.9%
500621	ACA	779	54	10,793	276	361	1,875		41.5%	2.9%	14.7%	19.3%
780116	Normal	0	0	703	1	3	380		0.1%	0.0%	0.2%	0.7%
780687	Normal	1	0	1,754	4	1	564		0.2%	0.0%	0.7%	0.1%

SampleID	Pathology	Theoretical mpQuARTS							% Methylation			
		NDRG4	BMP3	BTACT	VAV3	SFMB2	ZDHHC1		% NDRG4	% BMP3	% VAV3	% SFMB2
500237	AA	1,495	1,090	158,172	25,368	3,251	65,880		0.4%	1.0%	40.0%	2.7%
500621	ACA	15,959	1,112	221,049	5,643	7,397	38,418		13.9%	2.3%	15.0%	11.9%
780116	Normal	8	0	34,407	14	54	7,776		0.0%	0.0%	0.3%	0.0%
780687	Normal	18	0	35,925	77	11	11,545		0.0%	0.0%	0.4%	0.1%

SampleID	Pathology	Measured mpQuARTS							% Methylation			
		NDRG4	BMP3	BTACT	VAV3	S897	ZDHHC1		% NDRG4	% BMP3	% VAV3	% SFMB2
500237	AA	235	572	47,821	23,748	1,575	59,396		0.4%	1.0%	40.0%	2.7%
500621	ACA	5,320	869	66,220	5,735	4,582	38,352		13.9%	2.3%	15.0%	11.9%
780116	Normal	0	0	7,956	26	3	7,705		0.0%	0.0%	0.3%	0.0%
780687	Normal	0	0	6,418	37	13	10,298		0.0%	0.0%	0.4%	0.1%
No Target Control	-	0	0	0	23	0	0					

SampleID	Pathology	Back calculated QuARTS							% Methylation			
		NDRG4	BMP3	BTACT	VAV3	SFMB2	ZDHHC1		% NDRG4	% BMP3	% VAV3	% SFMB2
500237	AA	11	28	2,335	1,150	77	2,900		0.4%	1.0%	40.0%	2.7%
500621	ACA	260	42	3,233	280	224	1,873		13.9%	2.3%	15.0%	11.9%
780116	Normal	0	0	388	1	0	376		0.0%	0.0%	0.3%	0.0%
780687	Normal	0	0	313	2	1	503		0.0%	0.0%	0.4%	0.1%
No Target Control	-	0	0	0	23	0	0					

SampleID	Pathology	multiplex PCR Efficiency							% Methylation			
		NDRG4	BMP3	BTACT	VAV3	S897	ZDHHC1		% NDRG4	% BMP3	% VAV3	% SFMB2
500237	AA	16%	52%	30%	94%	48%	90%		0.4%	1.0%	40.0%	2.7%
500621	ACA	33%	78%	30%	102%	62%	100%		13.9%	2.3%	15.0%	11.9%
780116	Normal	-	-	55%	-	-	99%		0.0%	0.0%	0.3%	0.0%
780687	Normal	-	-	13%	-	-	89%		0.0%	0.0%	0.4%	0.1%

FIG. 10A

Multiplex PreAmp + PCR-Flap Assay Strands/rxn										
SampleID	final Site Category	Histology, Cancer	grade	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	
1503401149	Colorectal/Normal			0	863	119,214	0	0	400	
1503401151	Colorectal/Normal	Adenocarcinoma	grade 2/well	20	77	1,343	18	11	131	
1503401152	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	99	382	47	7	471	
1503401153	Colorectal/Normal			0	0	1,602	0	0	32	
1503401154	Colorectal/Normal			0	0	897	0	0	0	
1503401156	Colorectal/Normal			0	0	1,868	0	0	0	
1503401157	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	0	0	12,495	0	1	10,660	
1503401158	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	125,107	72,687	113,595	127,562	21,736	125,381	
1503401160	Stomach	Adenocarcinoma	grade 4/poorly	25	5	4,155	123	4	151	
1503401161	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	17,400	12,985	21,292	9,750	5,226	28,690	
1503401162	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	14,817	46,702	66,058	7	135,554	
1503401163	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	1,375	0	0	484	
1503401164	Colorectal/Normal			0	0	1,588	0	0	38	
1503401165	Stomach	Adenocarcinoma	U	0	0	9,100	0	0	0	
1503401166	Stomach	Adenocarcinoma	grade 3/moderate	0	0	5,876	0	0	133	
1503401167	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	60,317	1	102,684	70,060	16,476	86,062	
1503401168	Stomach	Adenocarcinoma	grade 3/moderate	0	0	941	0	0	649	
1503401169	Colorectal/Normal			0	0	1,989	0	0	68	
1503401170	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	1,982	21	0	16	
1503401171	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,423	0	0	0	
1503401172	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	581	2,214	5,814	2,368	108	4,724	
1503401173	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	3,096	0	35	864	
1503401175	Colorectal/Normal			0	0	3,101	0	0	26	
1503401176	Colorectal/Normal			0	0	866	0	0	11	
1503401177	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	0	0	1,316	0	0	0	
1503401178	Colorectal/Normal			0	32	228,629	0	0	45	
1503401179	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	2,674	50	4	0	
1503401180	Stomach	Adenocarcinoma	grade 1	0	1	1,076	1	0	104	

Direct PCR-Flap Assay (NO PreAmp)					
NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl
0	41	15,388	0	0	10
11	4	148	9	3	8
0	4	47	5	1	20
0	0	110	0	0	0
0	0	46	0	0	0
0	0	161	0	0	2
0	0	1,897	0	0	397
3,551	1,636	4,691	3,705	829	3,109
15	5	721	8	2	9
932	334	1,525	389	307	924
0	310	3,367	2,036	0	3,624
0	0	80	0	0	25
0	2	65	0	0	0
0	0	106	0	0	0
0	0	178	0	0	8
1,732	0	3,661	1,277	408	1,980
0	0	125	0	0	26
0	0	175	0	0	4
0	0	131	0	0	0
0	0	125	0	0	2
65	66	413	102	6	176
0	0	357	0	1	30
0	0	132	0	0	2
0	0	100	0	0	2
0	0	119	0	0	0
0	9	25,397	0	0	6
4	1	116	1	0	3
0	0	61	2	0	2

FIG. 10B

Multiplex Pre-Amp + PCR Flap Assay Strands/rxn											Direct PCR-Flap Assay (No PCR Pre-Amp)					
SampleID	final Site Category	Histology, Cancer	grade	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCT1		NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCT1
1503401181	Stomach	Adenocarcinoma	grade 3/moderate	0	0	16,130	0	0	0		0	0	213	0	0	0
1503401182	Stomach	Adenocarcinoma	U	80	42	2,801	375	0	689		19	1	155	10	1	19
1503401183	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	1,369	10	0	52		0	0	105	0	0	1
1503401184	Colorectal/Normal			0	0	1,993	0	0	19		0	0	90	0	0	3
1503401185	Colorectal/Normal			0	0	2,214	0	0	38		0	0	86	0	0	4
1503401186	Stomach	Adenocarcinoma	grade 4/poorly	0	0	3,013	0	0	154		0	2	234	0	0	3
1503401187	Colorectal/Normal			0	0	8,627	0	0	0		0	0	368	0	0	1
1503401188	Bile duct			0	0	929	0	0	21		0	0	126	0	0	4
1503401189	Colorectal/Normal			0	0	606	0	0	0		0	0	57	0	0	0
1503401190	Colorectal/Normal			0	0	1,659	0	0	4		0	0	71	0	0	0
1503401191	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	13,862	0	6,782	17,430	4,635	19,018		469	0	943	574	213	502
1503401192	Colorectal/Normal			0	0	695	0	0	21		0	0	64	0	0	0
1503401193	Colorectal/Normal	Other	U	46,219	17,329	26,613	57,917	7,921	58,169		1,829	480	2,239	2,271	421	1,939
1503401194	Colorectal/Normal	Squamous Cell	grade 3/moderate	33,593	16,483	13,425	240	3,444	51,199		1,180	324	1,909	13	183	1,922
1503401195	Colorectal/Normal	Adenocarcinoma	U	2,137	1,377	6,043	3,300	354	5,665		179	44	562	148	43	244
1503401196	Stomach	Adenocarcinoma	grade 3/moderate	27	119	561	218	62	347		9	3	46	2	0	8
1503401197	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	474	0	1,556	1,093	33	2,233		23	0	96	21	2	37
1503401198	Colorectal/Normal		grade 4/poorly	28	451	4,264	110	0	857		16	9	125	5	0	17
1507705066	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,755	0	0	22		0	0	82	0	0	0
1507705067	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,965	0	0	42		0	0	118	0	0	2
1507705068	Colorectal/Normal			0	0	4,406	0	0	0		0	0	100	0	0	0
1507705070	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	10,618	647	12,943	15,040	2,671	15,743		262	19	713	475	103	406

FIG. 10C

Multiplex Pre-Amp + PCR-Flap Assay															
SampleID	final Site Category	Histology, Cancer	grade	Strands/rxn					Direct Flap Assay (NO Pre-Amp)						
				NDRG4	BMP3	BTACT	VAV3	S897	ZDHHC1	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHC1
1507705071	Colorectal/Normal			0	0	1,622	0	0	19	0	0	97	0	0	5
1507705072	Colorectal/Normal			0	0	5,291	0	0	183	0	0	338	0	0	2
1507705073	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	42	0	3,370	0	32	291	16	0	344	0	3	19
1507705074	Stomach	Adenocarcinoma	grade 4/poorly	0	6	1,076	101	0	198	2	0	147	0	0	11
1507705075	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	49	0	2,257	0	15	443	10	0	122	0	0	9
1507705076	Colorectal/Normal			0	0	1,614	0	0	0	0	0	61	0	0	0
1507705077	Stomach	Adenocarcinoma	grade 4/poorly	0	0	2,391	0	0	0	3	0	125	0	0	3
1507705078	Stomach	Adenocarcinoma	grade 4/poorly	0	0	3,512	0	0	6	0	0	111	0	0	2
1507705079	Stomach	Adenocarcinoma	grade 4/poorly	0	0	6,760	0	0	0	0	0	249	0	0	5
1507705080	Stomach	Adenocarcinoma	grade 4/poorly	0	21	996	0	0	22	0	0	138	0	0	4
1507705081	Stomach			0	0	2,582	0	0	0	0	0	157	0	0	4
1507705082	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,494	0	0	29	0	0	77	0	0	0
1507705083	Stomach	Adenocarcinoma	grade 3/moderate	2	25	3,752	26	0	69	0	0	230	1	0	4
1507705084	Colorectal/Normal			0	0	2,562	0	0	67	0	0	42	0	0	0
1507705085	Stomach	Adenocarcinoma	grade 4/poorly	0	7	3,533	0	0	0	0	0	101	0	0	0
1507705086	Colorectal/Normal			0	0	2,289	0	0	15	0	0	56	0	0	2
1507705087	Stomach	Adenocarcinoma	grade 4/poorly	0	0	2,005	0	0	71	0	0	197	0	0	2
1507705088	Colorectal/Normal			0	0	345	0	0	3	0	0	31	0	0	0
1508204660	Other			0	0	1,285	0	0	294	0	0	108	0	0	11
1508204661	Colorectal/Normal			0	5	35,774	0	0	664	0	5	1,587	0	0	12
1508204662	Colorectal/Normal	Adenocarcinoma	grade 2/well	0	9	1,086	0	0	56	0	0	62	0	0	9
1508204663	Stomach	Adenocarcinoma	U	0	0	2,169	0	0	0	0	0	109	0	0	0
1508204664	Stomach	Adenocarcinoma	grade 3/moderate	0	0	1,918	0	0	72	0	0	255	0	0	10
1508204665	Stomach	Adenocarcinoma	grade 4/poorly	0	0	3,412	0	0	95	0	0	216	0	0	2
1508204666	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	5,015	7,235	20,993	16,773	3,667	34,878	207	105	663	419	108	816

FIG. 10D

Multiplex PreAmp + PCR Flap Assay															
SampleID	final Site Category	Histology, Cancer	grade	Strands/rxn					%Methylation						
				NDRG4	BMP3	BTACT	VAV3	S897	ZDHHG1	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHG1
1503401149	Colorectal/Normal			0	863	119,214	0	0	400	0.0%	0.7%	100.0%	0.0%	0.0%	0.3%
1503401151	Colorectal/Normal	Adenocarcinoma	grade 2/well	20	77	1,343	18	11	131	1.5%	5.7%	100.0%	1.3%	0.8%	9.8%
1503401152	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	99	382	47	7	471	0.0%	25.9%	100.0%	12.2%	1.8%	123.5%
1503401153	Colorectal/Normal			0	0	1,602	0	0	32	0.0%	0.0%	100.0%	0.0%	0.0%	2.0%
1503401154	Colorectal/Normal			0	0	897	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401156	Colorectal/Normal			0	0	1,868	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401157	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	0	0	12,495	0	1	10,660	0.0%	0.0%	100.0%	0.0%	0.0%	85.3%
1503401158	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	125,107	72,687	113,595	127,562	21,736	125,381	110.1%	64.0%	100.0%	112.3%	19.1%	110.4%
1503401160	Stomach	Adenocarcinoma	grade 4/poorly	25	5	4,155	123	4	151	0.6%	0.1%	100.0%	3.0%	0.1%	3.6%
1503401161	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	17,400	12,985	21,292	9,750	5,226	28,690	81.7%	61.0%	100.0%	45.8%	24.5%	134.7%
1503401162	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	14,817	46,702	66,058	7	135,554	0.0%	31.7%	100.0%	141.4%	0.0%	290.3%
1503401163	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	1,375	0	0	484	0.0%	0.0%	100.0%	0.0%	0.0%	35.2%
1503401164	Colorectal/Normal			0	0	1,588	0	0	38	0.0%	0.0%	100.0%	0.0%	0.0%	2.4%
1503401165	Stomach	Adenocarcinoma	U	0	0	9,100	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401166	Stomach	Adenocarcinoma	grade 3/moderate	0	0	5,876	0	0	133	0.0%	0.0%	100.0%	0.0%	0.0%	2.3%
1503401167	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	60,317	1	102,684	70,060	16,476	86,062	58.7%	0.0%	100.0%	68.2%	16.0%	83.8%
1503401168	Stomach	Adenocarcinoma	grade 3/moderate	0	0	941	0	0	649	0.0%	0.0%	100.0%	0.0%	0.0%	69.0%
1503401169	Colorectal/Normal			0	0	1,989	0	0	68	0.0%	0.0%	100.0%	0.0%	0.0%	3.4%
1503401170	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	1,982	21	0	16	0.0%	0.0%	100.0%	1.0%	0.0%	0.8%
1503401171	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,423	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401172	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	581	2,214	5,814	2,368	108	4,724	10.0%	38.1%	100.0%	40.7%	1.9%	81.3%
1503401173	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	3,096	0	35	864	0.0%	0.0%	100.0%	0.0%	1.1%	27.9%
1503401175	Colorectal/Normal			0	0	3,101	0	0	26	0.0%	0.0%	100.0%	0.0%	0.0%	0.8%
1503401176	Colorectal/Normal			0	0	866	0	0	11	0.0%	0.0%	100.0%	0.0%	0.0%	1.3%
1503401177	Colorectal/Normal	Adenocarcinoma	grade 4/poorly	0	0	1,316	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401178	Colorectal/Normal			0	32	228,629	0	0	45	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1503401179	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	0	0	2,674	50	4	0	0.0%	0.0%	100.0%	1.9%	0.2%	0.0%
1503401180	Stomach	Adenocarcinoma	grade 1	0	1	1,076	1	0	104	0.0%	0.1%	100.0%	0.1%	0.0%	9.7%

FIG. 10E

Multiplex PreAmp + PCR Flap Assay										%Methylation									
SampleID	final Site Category	Histology, Cancer	grade	Strands/rxn					NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl					
1503401181	Stomach	Adenocarcinoma	grade 3/moderate						0	0	16,130	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%
1503401182	Stomach	Adenocarcinoma	U						80	42	2,801	375	0	689	2.9%	1.5%	100.0%	13.4%	0.0%
1503401183	Colorectal/Normal	Adenocarcinoma	grade 3/moderate						0	0	1,369	10	0	52	0.0%	0.0%	100.0%	0.7%	0.0%
1503401184	Colorectal/Normal								0	0	1,993	0	0	19	0.0%	0.0%	100.0%	0.0%	0.0%
1503401185	Colorectal/Normal								0	0	2,214	0	0	38	0.0%	0.0%	100.0%	0.0%	0.0%
1503401186	Stomach	Adenocarcinoma	grade 4/poorly						0	0	3,013	0	0	154	0.0%	0.0%	100.0%	0.0%	0.0%
1503401187	Colorectal/Normal								0	0	8,627	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%
1503401188	Bile duct								0	0	929	0	0	21	0.0%	0.0%	100.0%	0.0%	0.0%
1503401189	Colorectal/Normal								0	0	606	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%
1503401190	Colorectal/Normal								0	0	1,659	0	0	4	0.0%	0.0%	100.0%	0.0%	0.0%
1503401191	Colorectal/Normal	Adenocarcinoma	grade 3/moderate						13,862	0	6,782	17,430	4,635	19,018	204.4%	0.0%	100.0%	257.0%	68.3%
1503401192	Colorectal/Normal								0	0	695	0	0	21	0.0%	0.0%	100.0%	0.0%	0.0%
1503401193	Colorectal/Normal	Other	U						46,219	17,329	26,613	57,917	7,921	58,169	173.7%	65.1%	100.0%	217.6%	29.8%
1503401194	Colorectal/Normal	Squamous Cell	grade 3/moderate						33,593	16,483	13,425	240	3,444	51,199	250.2%	122.8%	100.0%	1.8%	25.7%
1503401195	Colorectal/Normal	Adenocarcinoma	U						2,137	1,377	6,043	3,300	354	5,665	35.4%	22.8%	100.0%	54.6%	5.9%
1503401196	Stomach	Adenocarcinoma	grade 3/moderate						27	119	561	218	62	347	4.9%	21.2%	100.0%	38.9%	11.1%
1503401197	Colorectal/Normal	Adenocarcinoma	grade 3/moderate						474	0	1,556	1,093	33	2,233	30.5%	0.0%	100.0%	70.2%	2.1%
1503401198	Colorectal/Normal		grade 4/poorly						28	451	4,264	110	0	857	0.7%	10.6%	100.0%	2.6%	0.0%
1507705066	Stomach	Adenocarcinoma	grade 4/poorly						0	0	1,755	0	0	22	0.0%	0.0%	100.0%	0.0%	0.0%
1507705067	Stomach	Adenocarcinoma	grade 4/poorly						0	0	1,965	0	0	42	0.0%	0.0%	100.0%	0.0%	0.0%
1507705068	Colorectal/Normal								0	0	4,406	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%
1507705070	Colorectal/Normal	Adenocarcinoma	grade 4/poorly						10,618	647	12,943	15,040	2,671	15,743	82.0%	5.0%	100.0%	116.2%	20.6%

FIG. 10F

SampleID	final Site Category	Histology, Cancer	Grade	Multiplex PreAmp + PCR Flap Assay Strands/rxn						%Methylation					
				NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl
1507705071	Colorectal/Normal			0	0	1,622	0	0	19	0.0%	0.0%	100.0%	0.0%	0.0%	1.1%
1507705072	Colorectal/Normal			0	0	5,291	0	0	183	0.0%	0.0%	100.0%	0.0%	0.0%	3.5%
1507705073	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	42	0	3,370	0	32	291	1.2%	0.0%	100.0%	0.0%	1.0%	8.6%
1507705074	Stomach	Adenocarcinoma	grade 4/poorly	0	6	1,076	101	0	198	0.0%	0.5%	100.0%	9.4%	0.0%	18.4%
1507705075	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	49	0	2,257	0	15	443	2.2%	0.0%	100.0%	0.0%	0.7%	19.6%
1507705076	Colorectal/Normal			0	0	1,614	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1507705077	Stomach	Adenocarcinoma	grade 4/poorly	0	0	2,391	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1507705078	Stomach	Adenocarcinoma	grade 4/poorly	0	0	3,512	0	0	6	0.0%	0.0%	100.0%	0.0%	0.0%	0.2%
1507705079	Stomach	Adenocarcinoma	grade 4/poorly	0	0	6,760	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1507705080	Stomach	Adenocarcinoma	grade 4/poorly	0	21	996	0	0	22	0.0%	2.1%	100.0%	0.0%	0.0%	2.2%
1507705081	Stomach			0	0	2,582	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1507705082	Stomach	Adenocarcinoma	grade 4/poorly	0	0	1,494	0	0	29	0.0%	0.0%	100.0%	0.0%	0.0%	1.9%
1507705083	Stomach	Adenocarcinoma	grade 3/moderate	2	25	3,752	26	0	69	0.1%	0.7%	100.0%	0.7%	0.0%	1.8%
1507705084	Colorectal/Normal			0	0	2,562	0	0	67	0.0%	0.0%	100.0%	0.0%	0.0%	2.6%
1507705085	Stomach	Adenocarcinoma	grade 4/poorly	0	7	3,533	0	0	0	0.0%	0.2%	100.0%	0.0%	0.0%	0.0%
1507705086	Colorectal/Normal			0	0	2,289	0	0	15	0.0%	0.0%	100.0%	0.0%	0.0%	0.7%
1507705087	Stomach	Adenocarcinoma	grade 4/poorly	0	0	2,005	0	0	71	0.0%	0.0%	100.0%	0.0%	0.0%	3.5%
1507705088	Colorectal/Normal			0	0	345	0	0	3	0.0%	0.0%	100.0%	0.0%	0.0%	0.9%
1508204660	Other			0	0	1,285	0	0	294	0.0%	0.0%	100.0%	0.0%	0.0%	22.9%
1508204661	Colorectal/Normal			0	5	35,774	0	0	664	0.0%	0.0%	100.0%	0.0%	0.0%	1.9%
1508204662	Colorectal/Normal	Adenocarcinoma	grade 2/well	0	9	1,086	0	0	56	0.0%	0.8%	100.0%	0.0%	0.0%	5.2%
1508204663	Stomach	Adenocarcinoma	U	0	0	2,169	0	0	0	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
1508204664	Stomach	Adenocarcinoma	grade 3/moderate	0	0	1,918	0	0	72	0.0%	0.0%	100.0%	0.0%	0.0%	3.8%
1508204665	Stomach	Adenocarcinoma	grade 4/poorly	0	0	3,412	0	0	95	0.0%	0.0%	100.0%	0.0%	0.0%	2.8%
1508204666	Colorectal/Normal	Adenocarcinoma	grade 3/moderate	5,015	7,235	20,993	16,773	3,667	34,878	23.9%	34.5%	100.0%	79.9%	17.5%	166.1%

FIG. 10G

Input strands calculated from Multiplex + PCR Flap assay						
SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHC1
1503401149	0	42	5821	0	0	20
1503401151	1	4	66	1	1	6
1503401152	0	5	19	2	0	23
1503401153	0	0	78	0	0	2
1503401154	0	0	44	0	0	0
1503401156	0	0	91	0	0	0
1503401157	0	0	610	0	0	521
1503401158	6109	3549	5547	6229	1061	6122
1503401160	1	0	203	6	0	7
1503401161	850	634	1040	476	255	1401
1503401162	0	723	2280	3226	0	6619
1503401163	0	0	67	0	0	24
1503401164	0	0	78	0	0	2
1503401165	0	0	444	0	0	0
1503401166	0	0	287	0	0	6
1503401167	2945	0	5014	3421	804	4202
1503401168	0	0	46	0	0	32
1503401169	0	0	97	0	0	3
1503401170	0	0	97	1	0	1
1503401171	0	0	69	0	0	0
1503401172	28	108	284	116	5	231
1503401173	0	0	151	0	2	42
1503401175	0	0	151	0	0	1
1503401176	0	0	42	0	0	1
1503401177	0	0	64	0	0	0
1503401178	0	2	1164	0	0	2
1503401179	0	0	131	2	0	0
1503401180	0	0	53	0	0	5

%Recovery (compared to Direct Flap Assay)						
NDRG4	BMP3	BTACT	VAV3	S897	ZDHC1	
-	103%	38%	-	-	-	204%
9%	97%	44%	10%	17%	17%	80%
-	121%	39%	43%	55%	55%	112%
-	-	71%	-	-	-	-
-	-	94%	-	-	-	-
-	-	57%	-	0%	0%	0%
-	-	32%	-	-	-	131%
172%	217%	118%	168%	128%	128%	197%
8%	5%	28%	79%	9%	9%	81%
91%	190%	68%	122%	83%	83%	152%
-	233%	68%	158%	84%	84%	183%
-	-	83%	-	63%	63%	94%
-	-	120%	-	-	-	-
-	-	419%	-	-	-	-
-	-	161%	-	-	-	80%
170%	-	137%	268%	197%	197%	212%
-	-	37%	-	132%	132%	122%
-	-	55%	-	-	-	87%
-	-	74%	-	-	-	-
-	-	56%	-	-	-	-
44%	165%	69%	113%	93%	93%	131%
-	-	42%	-	121%	121%	140%
-	-	115%	-	-	-	66%
-	-	42%	-	-	-	26%
-	-	54%	-	-	-	-
-	18%	44%	-	-	-	40%
-	-	113%	304%	-	-	0%
-	-	86%	2%	0%	0%	254%

Direct Flap Assay (NO Pre-Amp)								
SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHC1		
1503401149	0	41	15,388	0	0	10		
1503401151	11	4	148	9	3	8		
1503401152	0	4	47	5	1	20		
1503401153	0	0	110	0	0	0		
1503401154	0	0	46	0	0	0		
1503401156	0	0	161	0	0	2		
1503401157	0	0	1,897	0	0	397		
1503401158	3,551	1,636	4,691	3,705	829	3,109		
1503401160	15	5	721	8	2	9		
1503401161	932	334	1,525	389	307	924		
1503401162	0	310	3,367	2,036	0	3,624		
1503401163	0	0	80	0	0	25		
1503401164	0	2	65	0	0	0		
1503401165	0	0	106	0	0	0		
1503401166	0	0	178	0	0	8		
1503401167	1,732	0	3,661	1,277	408	1,980		
1503401168	0	0	125	0	0	26		
1503401169	0	0	175	0	0	4		
1503401170	0	0	131	0	0	0		
1503401171	0	0	125	0	0	2		
1503401172	65	66	413	102	6	176		
1503401173	0	0	357	0	1	30		
1503401175	0	0	132	0	0	2		
1503401176	0	0	100	0	0	2		
1503401177	0	0	119	0	0	0		
1503401178	0	9	25,397	0	0	6		
1503401179	4	1	116	1	0	3		
1503401180	0	0	61	2	0	2		

FIG. 10H

Input strands calculated from Multiplex + PCR Flap assay						
SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl
1503401181	0	0	788	0	0	0
1503401182	4	2	137	18	0	34
1503401183	0	0	67	0	0	3
1503401184	0	0	97	0	0	1
1503401185	0	0	108	0	0	2
1503401186	0	0	147	0	0	8
1503401187	0	0	421	0	0	0
1503401188	0	0	45	0	0	1
1503401189	0	0	30	0	0	0
1503401190	0	0	81	0	0	0
1503401191	677	0	331	851	226	929
1503401192	0	0	34	0	0	1
1503401193	2257	846	1299	2828	387	2840
1503401194	1640	805	655	12	168	2500
1503401195	104	67	295	161	17	277
1503401196	1	6	27	11	3	17
1503401197	23	0	76	53	2	109
1503401198	1	22	208	5	0	42
1507705066	0	0	86	0	0	1
1507705067	0	0	96	0	0	2
1507705068	0	0	215	0	0	0
1507705070	518	32	632	734	130	769

%Recovery (compared to Direct Flap Assay)						
NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	
-	-	370%	-	-	-	
20%	157%	88%	180%	0%	181%	
-	-	64%	-	-	171%	
-	-	108%	-	-	30%	
-	-	125%	-	-	49%	
-	-	63%	-	-	287%	
-	-	115%	-	-	0%	
-	-	36%	-	-	25%	
-	-	52%	-	-	-	
-	-	113%	-	-	-	
144%	-	35%	148%	106%	185%	
-	-	53%	-	-	228%	
123%	176%	58%	125%	92%	146%	
139%	249%	34%	87%	92%	130%	
58%	153%	53%	109%	40%	114%	
15%	224%	60%	641%	31005%	209%	
103%	-	79%	259%	86%	296%	
8%	254%	166%	106%	158%	246%	
-	-	104%	-	-	-	
-	-	81%	-	-	106%	
-	-	215%	-	-	-	
198%	163%	89%	155%	126%	189%	

Direct Flap Assay (NO Pre-Amp)						
SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl
1503401181	0	0	213	0	0	0
1503401182	19	1	155	10	1	19
1503401183	0	0	105	0	0	1
1503401184	0	0	90	0	0	3
1503401185	0	0	86	0	0	4
1503401186	0	2	234	0	0	3
1503401187	0	0	368	0	0	1
1503401188	0	0	126	0	0	4
1503401189	0	0	57	0	0	0
1503401190	0	0	71	0	0	0
1503401191	469	0	943	574	213	502
1503401192	0	0	64	0	0	0
1503401193	1,829	480	2,239	2,271	421	1,939
1503401194	1,180	324	1,909	13	183	1,972
1503401195	179	44	562	148	43	244
1503401196	9	3	46	2	0	8
1503401197	23	0	96	21	2	37
1503401198	16	9	125	5	0	17
1507705066	0	0	82	0	0	0
1507705067	0	0	118	0	0	2
1507705068	0	0	100	0	0	0
1507705070	262	19	713	475	103	406

FIG. 10I

Input strands calculated from Multiplex + PCR Flap assay						%Recovery (compared to Direct Flap Assay)						Direct Flap Assay (NO Pre-Amp)								
SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	SampleID	NDRG4	BMP3	BTACT	VAV3	S897	ZDHHCl	
	1507705071	0	0	79	0	0	1	-	81%	-	-	18%	1507705071	0	0	97	0	0	5	
	1507705072	0	0	258	0	0	9	-	77%	-	-	401%	1507705072	0	0	338	0	0	2	
	1507705073	2	0	165	0	2	14	13%	-	48%	-	74%	1507705073	16	0	344	0	3	19	
	1507705074	0	0	53	5	0	10	1%	-	36%	-	90%	1507705074	2	0	147	0	0	11	
	1507705075	2	0	110	0	1	22	23%	-	90%	-	242%	1507705075	10	0	122	0	0	9	
	1507705076	0	0	79	0	0	0	-	-	129%	-	0%	1507705076	0	0	61	0	0	0	
	1507705077	0	0	117	0	0	0	-	-	93%	0%	0%	1507705077	3	0	125	0	0	3	
	1507705078	0	0	171	0	0	0	-	-	155%	-	17%	1507705078	0	0	111	0	0	2	
	1507705079	0	0	330	0	0	0	-	-	132%	-	0%	1507705079	0	0	249	0	0	5	
	1507705080	0	1	49	0	0	1	-	17520%	35%	-	29%	1507705080	0	0	138	0	0	4	
	1507705081	0	0	126	0	0	0	-	-	80%	-	0%	1507705081	0	0	157	0	0	4	
	1507705082	0	0	73	0	0	1	-	-	95%	-	-	1507705082	0	0	77	0	0	0	
	1507705083	0	1	183	1	0	3	-	-	80%	106%	24%	93%	1507705083	0	0	230	1	0	4
	1507705084	0	0	125	0	0	3	-	-	296%	-	-	1507705084	0	0	42	0	0	0	
	1507705085	0	0	173	0	0	0	-	-	171%	-	-	1507705085	0	0	101	0	0	0	
	1507705086	0	0	112	0	0	1	-	-	200%	-	47%	1507705086	0	0	56	0	0	2	
	1507705087	0	0	98	0	0	3	-	-	50%	-	212%	1507705087	0	0	197	0	0	2	
	1507705088	0	0	17	0	0	0	-	-	54%	-	-	1507705088	0	0	31	0	0	0	
	1508204660	0	0	63	0	0	14	-	-	58%	-	44%	131%	1508204660	0	0	108	0	0	11
	1508204661	0	0	1747	0	0	32	-	5%	110%	-	276%	1508204661	0	5	1,587	0	0	12	
	1508204662	0	0	53	0	0	3	-	-	85%	-	17%	30%	1508204662	0	0	62	0	0	9
	1508204663	0	0	106	0	0	0	-	-	97%	-	-	1508204663	0	0	109	0	0	0	
	1508204664	0	0	94	0	0	4	-	-	37%	-	8%	37%	1508204664	0	0	255	0	0	10
	1508204665	0	0	167	0	0	5	-	-	77%	-	-	1508204665	0	0	216	0	0	2	
	1508204666	245	353	1025	819	179	1703	118%	336%	154%	195%	165%	209%	1508204666	207	105	663	419	108	816


FIG. 11A


FIG. 11B


FIG. 11C


FIG. 12A


FIG. 12B


FIG. 12C

FIG. 13A

	Description	Sequence (all are shown 5' to 3')
SEQ ID NO:16	VAV3 Outer Reverse Primer	CAACCGCCGACCCCTTC
SEQ ID NO:17	VAV3 PCR/Flap assay target region	TCGGAGTCGAGTTAGCGCGCGCTCCGCGATTCTGTTAGTCGCGGTTTTTGTT
SEQ ID NO:18	VAV3 PCR/Flap assay Forward Primer	TCGGAGTCGAGTTTAGCGC
SEQ ID NO:19	VAV3 PCR/Flap assay Reverse Primer	AACAAAAACCGCGACTAACGA
SEQ ID NO:20	VAV3 Flap oligonucleotide	CCACGGACGCGCGTTCCGCA/3C6/
SEQ ID NO:21	BMP3 Target DNA	CTGGGTACGCGAGCAAGTGGGCTGGCCGCTATCTCGCTGCACCCGGCCGCTCCGGGCTCCGTGCGCCCTCGCCCCCAGC TGGTTTGAGGTTCAACCCTCGGCTCCGCGCCGGCTCCTTGGCGCTTCGGAGTGTCCCGACGACGCGCGGAGCCGACGCGC CGCGGGGTACCTAGCCATGGCTGGGGCGAGCAGGCTGCTCTT
SEQ ID NO:22	BMP3 Target region FIG. 5	GGGCTCCGTGCGCCCTCGCCCAAGTGGTTTGGAGTTCAACCCCTCGGCTCCGCGCCGGCTCCTTGGCCCTTCGGAGTGTCCC GCAGCGACCGCGGAGCGACGCGCCGCGCGGTACCTAGCCATGGCTGGGGCGA
SEQ ID NO:23	BMP3 Bisulfite converted DNA	TTGGTTAGCGTAGTAAGTGGGTTGGTCGTTATTCGTTGATTCGGTCGCGTTTCGGGTTTCGTGCGTTTCGTTTATGTTG GTTTGGAGTTTAATTTTCGGTTTCGTGCTCGGTTTTTCGTTTTTCGGAGTGTTCGTAGCGACGTCGGGAGTTCGACGCGTCGC GCGGATTTAGTTATGTTGGGCGGAGTAGTTGTTTTT
SEQ ID NO:24	BMP3 Bisulfite converted region FIG. 5	CGGGTTTCGTGCGTTTCGTTTATGTTAGTTGGTTTGGAGTTTAATTTTCGGTTTCGTGCTCGGTTTTTCGTTTTTCGGAGTGTTCGT AGCGACGTCGGGAGTCGACGCGTCGCGCGGTAATTTAGTTATGTTGGGGCGA
SEQ ID NO:25	BMP3 Outer Forward Primer	GGTTTCGTGCGTTTCGTTTATGTT
SEQ ID NO:26	BMP3 Outer Reverse Primer	CCAACCAATAAATACCCGCG
SEQ ID NO:27	BMP3 PCR/Flap assay target region	GTTTAATTTTCGGTTTCGTGCTCGGTTTTTCGTTTTTCGGAGTGTTCGTAGCG
SEQ ID NO:28	BMP3 PCR/Flap assay Forward Primer	GTTTAATTTTCGGTTTCGTGCTC
SEQ ID NO:29	BMP3 PCR/Flap assay Reverse Primer	CGCTACGAAACACTCCGA
SEQ ID NO:30	BMP3 Flap oligonucleotide	CGCCGAGCGGTTTTTTCG/3C6/

FIG. 13B

FIG. 13C

	Description	Sequence (all are shown 5' to 3')
SEQ ID NO:46	Beta Actin Outer Reverse Primer	CTACTTAATACACACTCCAAACCACT
SEQ ID NO:47	Beta Actin PCR/Flap assay target region	TTTGTTTTTTGATTAGGTGTTAAGATAGTGTGTGGGTAGGTATTAATAATTGGTTTGTGTGATAAAGGTTATGAGGTTGGTGGT
SEQ ID NO:48	Beta Actin PCR/Flap assay Forward Primer	G
SEQ ID NO:49	Beta Actin PCR/Flap assay Reverse Primer	TTTGTTTTTTGATTAGGTGTTTAAAGA
SEQ ID NO:50	Beta Actin Flap oligonucleotide	CACCAACCTCATAACCTTATC
SEQ ID NO:51	ZDHC1 Target DNA	GACGGGAG ATAGTGTGTGG/3C6/ CCGTGGACGAGATTCAGTGGCGCAGACGCGCTGGGAGCGCCGCTGCGCCCGGGGGCCGACAGCCCA CGTGGCGCGCAGGCGCTGCGCCCGCGTTTCTGTAGCCGAGCGGCGAGCCAGGGCGCGCGCGGAG GCTGCTCTGGCTTAGCTGG
SEQ ID NO:52	ZDHC1 Target region FIG. 5	GGGAGCGCGCTCTGGCCGCCCGGGGGCCGACAGCCACGCTGGCGCGGAGGCGCGTGGCGCCGCGTTT CGTAGCCCGAGCAGCGGCGAGCCAGGGCGCGGGGGCGGAGGCTGGCTAGCTGG
SEQ ID NO:53	ZDHC1 Bisulfite converted DNA	TCGTGGACGAGATTTAGTGGCGTAGACGCGTTTGGGTAGCGTCTTTGGTCTTTCGCGGGTCTGGGGTCGATAGTTACG TTGGCGGTAGCGCGTGCCTGCTCTTTCGTAGTTCGAGTAGCGGCGAGTTTAGGGCGTCTGGCGGCGGAGGTTG GTTGGTTAGTTGG
SEQ ID NO:54	ZDHC1 Bisulfite converted region FIG. 5	GGGTAGCGTCTTTTGGTCTTTCGCGGGTCTGGGGTCGATAGTTACGTTGGCGGGTAGGCGGTCGCTTCGCTTCG
SEQ ID NO:55	ZDHC1 Outer Forward Primer	TGAGTTCAGTAGCGGCGAGTTTAGGCGTCTGGCGGTCTGGGAGGTTGGTTGGTTAGTTGG
SEQ ID NO:56	ZDHC1 Outer Reverse Primer	AGCGTCGTTTGGTCGTTTC
SEQ ID NO:57	ZDHC1 PCR/Flap assay target region	GACGCCCTAAACTCGCC
SEQ ID NO:58	ZDHC1 PCR/Flap assay Forward Primer	GTCGGGGTCGATAGTTTACGTTGGCGGGTAGGCGCGTCTGCTCTTTCGTGAGTTCGAGT
SEQ ID NO:59	ZDHC1 PCR/Flap assay Reverse Primer	GTCGGGGTCGATAGTTTACG
SEQ ID NO:60	ZDHC1 Flap oligonucleotide	ACTCGAACTCACGAAAACG GACGGGAGGACGACGACG/3C6/

FIG. 13D

FIG. 13E

	Description	Sequence (all are shown 5' to 3')
SEQ ID NO:63	Bisulfite-treated Danio RASSF1 target (Fig. 1)	ATTAGAACGAGACGTTAAATTTATTAGTTGTTTGGAGTAAATAGCGTTGTTTAAAAATATTTTATAGTTATAAAATTTATTTAG TTTTAATTATGGTTTATTGAGTTATGTCGTTATTTTTCAGGATTTTAAAAATGGTAAATGTGAGTTTATCGAGTTGTAGGATTT GATTTGCAATGATCGTATTGAGTTGTTTATTTTATTTATTTATCGTGGTGTGTTTATTTGGATAGGTGGAGTAGAGGG AAGGTGGTCGTTATGGTGGCGAGCGCGTGGTGGAGGATTTTCGATTGGTGGACGTGTAACGTGTAATAGGACGAGGATATGATT TTTAGTTTGTAGTTAGATATAGTTGAGTTGGTGTGATTGTGGAGAGTTTATTTGGGGTTTGTATAGATAGAGTTTTTC CGCATGGTGGGCGAG
SEQ ID NO:64	ZF_RASSF1 UT forward primer	ACACGTCAGCCAATCGGG
SEQ ID NO:65	Zebrafish RASSF1 UT reverse primer	GACGCGAGGCGCGTGGCGC/3C6/
SEQ ID NO:66	Zebrafish RASSF1 UT Probe (Arm 3)	TGCGTATGGTGGGCGAG
SEQ ID NO:67	Zebrafish RASSF1 BT forward primer	CCTAATTTACACGTCACCAACCAATCGAA
SEQ ID NO:68	Zebrafish RASSF1 BT reverse primer	GACGCGAGGCGCGTGGCTTT/3C6/
SEQ ID NO:69	Zebrafish RASSF1 BT probe (Arm 3)	CCACGGACGGCGCGTGGCTTT/3C6/
SEQ ID NO:70	Zebrafish RASSF1 BT probe (Arm 5)	TCCAC/iMe-dC/GTGGTCCCCACTCTGGACAGGTGGAGCAGAGGGAAGGTGGTg/iMe-dC/GCATGGTGGG/iMe- dC/GAG/iMe-dC/G/iMe-dC/GTg/iMe-dC/GCCTGGAGGACCC/iMe-dC/GATTGGCTGA/iMe- dC/GTGTAAACACAGGA/iMe- dC/GAGGACATGACTTTACGCCCTGCAGCCAGACAGCTGAGCTGGTGTGACCTGTGTGGAGAGTTTCATCTGG
SEQ ID NO:71	Synthetic Zebrafish RASSF1 sense strand	CCAGATGAACCTCTCCACACAGGTCACACAGCTCAGCTGTGTCTGGTGCAGGGCTGAAAGTCATGTCCT/iMe- dC/GTCCTGGTTTACA/iMe-dC/GTCAGCCAAT/iMe-dC/GGGGTCTCTCCAGG/iMe-dC/GCA/iMe-dC/G/iMe-dC/GCT/iMe- dC/GCCACCATG/iMe-dC/GCACCACCTTCCCTCTGCTCCACCTGTCCAGAGTGGGCACCA/iMe-dC/GGTGGA GGTTATTTTGGTTTTTGGTTTTTCGG
SEQ ID NO:72	Synthetic Zebrafish RASSF1 antisense strand	TCCAACCTACTATATTTACGCGAA
SEQ ID NO:73	B3GALT6 BT Forward primer	CGCCGAGGCGGATTAGGG/3C6/
SEQ ID NO:74	B3GALT6 BT Reverse primer	GTGTTGTTTTTTTGTATTAGGTGTTTAAAGA
SEQ ID NO:75	B3GALT6 BT probe-Arm 1	
SEQ ID NO:76	Beta Actin BT PCR/Flap assay Forward Primer	CTTTACACCAACCTCATAACCTTATC
SEQ ID NO:77	Beta Actin BT PCR/Flap assay Reverse Primer	GACGCGGAGATAGTTGTGG /3C6/ /HEX/TCT/BHQ-1/AGCCGGTTTTCCGGCTGAGACCTCGGCG/3C6/ /FAM/TCT/BHQ-1/AGCCGGTTTTCCGGCTGAGACGTCCGTGG/3C6/ /Q670/TCT/BHQ-2/AGCCGGTTTTCCGGCTGAGACTCCGCGTC/3C6/
SEQ ID NO:78	Beta Actin probe-Arm 3	
SEQ ID NO:79	Arm 1 HEX FRET Cassette	
SEQ ID NO:80	Arm 5 FAM FRET Cassette	
SEQ ID NO:81	Arm 3 QUASAR-670 FRET Cassette	

FIG. 13F